Skip to Main Content

Yale Cardiovascular Medicine Grand Rounds - The Future of Cardiac Death and MI Prevention: Detection and Treatment of Vulnerable Plaque.

October 02, 2026

Dr. Henry Cabin Honorary Lecture



ID
14548

Transcript

  • 05:30Okay, everyone. I think we'll,
  • 05:32go ahead and get started,
  • 05:34since at least our guests
  • 05:35of honor are seated,
  • 05:38although there's a few people
  • 05:39coming in getting lunch.
  • 05:40First and foremost, I I
  • 05:42wanna,
  • 05:43welcome everyone,
  • 05:44here,
  • 05:46to our... The beginning of
  • 05:47our grand rounds, program for
  • 05:49this year
  • 05:50and also to welcome,
  • 05:52all the many people that
  • 05:53are in our different watch
  • 05:54parties across the state.
  • 05:56And thanks again to our
  • 05:58staff.
  • 06:00Many are in the back.
  • 06:01I won't embarrass them by
  • 06:03naming them all for helping
  • 06:04us coordinate,
  • 06:06this,
  • 06:07across, you know, all our
  • 06:08hospitals and our locations,
  • 06:11and to connect
  • 06:13and feed people in all
  • 06:14those locations as well, which
  • 06:15is which has been a
  • 06:16great,
  • 06:17and and very well received.
  • 06:18I also wanna take this
  • 06:19opportunity to thank,
  • 06:21Catherine,
  • 06:23Hattie, and Philippe,
  • 06:24for a really
  • 06:26wonderful job in in helping
  • 06:27coordinate this,
  • 06:29CME activity
  • 06:30and getting,
  • 06:31a a tremendous
  • 06:33panel of, speakers set up
  • 06:34for this year.
  • 06:36And and so,
  • 06:38and and and we're very
  • 06:39excited to have really
  • 06:43incredibly important member of our
  • 06:45cardiovascular community giving grand rounds
  • 06:47today. But before I do
  • 06:48that, let me just make
  • 06:49a few announcements, and and
  • 06:51I'll introduce Alexander to introduce
  • 06:53Greg.
  • 06:54So for everyone, just please
  • 06:56get your CME
  • 06:57credit.
  • 06:59Let's see if that can
  • 07:01go.
  • 07:03Oh, it's not going.
  • 07:07Okay. And that's just our
  • 07:08disclosure statement.
  • 07:10And this is,
  • 07:13just some information. So maybe
  • 07:15say a few words not
  • 07:16to embarrass doctor Kavan who's
  • 07:18in the audience,
  • 07:19but just to,
  • 07:20recognize the critically important
  • 07:23impact he's had,
  • 07:26at at this institution and
  • 07:27our hospital
  • 07:29over,
  • 07:30I think more than...
  • 07:32Aiming close to fifty years
  • 07:34now almost.
  • 07:36And so,
  • 07:37Henry,
  • 07:39did his
  • 07:41undergraduate degree at Penn.
  • 07:43He's from Great Neck originally
  • 07:44for those who, don't know
  • 07:46that, but I just sort
  • 07:47of sort out a way
  • 07:48in there. And, and then
  • 07:50joined Yale the...
  • 07:51As a medical student originally,
  • 07:54and then, joined our residency
  • 07:56at Yale New Haven Hospital.
  • 07:59You know, he
  • 08:01then took a sojourn
  • 08:03to the NIH for several
  • 08:04years where he was in
  • 08:06the pathology branch of the
  • 08:07NHLBI.
  • 08:09And, his first papers were
  • 08:10with Bill Roberts,
  • 08:12looking at
  • 08:13the impact of coronary artery
  • 08:15disease,
  • 08:16on aneurysmal formation
  • 08:18and the intersection between the
  • 08:20coronary anatomy and it's,
  • 08:22and when it's blocked and
  • 08:24aneurysm formation, which I think
  • 08:25is always really wonderful to
  • 08:27re... Review those papers,
  • 08:29which I have,
  • 08:30printed out in my, in
  • 08:31my files.
  • 08:32And then he came back
  • 08:34to complete his cardiology fellowship
  • 08:36and joined our faculty,
  • 08:38I believe in in,
  • 08:40in eighty
  • 08:41two,
  • 08:43and, and,
  • 08:45really was,
  • 08:47in so many different roles,
  • 08:48a member of our... A
  • 08:49a a critical member of
  • 08:50our faculty rising
  • 08:52within
  • 08:54a little more than a
  • 08:54decade to full professor
  • 08:56and serving in in multiple
  • 08:58different roles in our system
  • 08:59as not only medical director
  • 09:00of Yale New Haven
  • 09:02Hospital Heart and Vascular Center,
  • 09:03but as a vice chair
  • 09:05for department in clinical affairs
  • 09:06and then an interim chief,
  • 09:08role, for several years, before,
  • 09:11his his, becoming Emeritus in,
  • 09:14in two thousand and one.
  • 09:15So,
  • 09:16thank you, Henry, for twenty
  • 09:18twenty one. I'm sorry.
  • 09:20Not to that one.
  • 09:22Because you look really good
  • 09:23if you became Emeritus in
  • 09:24two thousand one.
  • 09:26Anyway, thank you, Henry, for
  • 09:27everything you've done for all
  • 09:28of us. For me, you've
  • 09:30been a a really great
  • 09:31colleague when I joined,
  • 09:33New City Institution and helped
  • 09:34shepherd my my development. So,
  • 09:36we we really use this
  • 09:37opportunity to thank you and,
  • 09:39and and bring a tremendous
  • 09:41speaker to to to the
  • 09:42campus on your behalf and
  • 09:43and celebrate you. So with
  • 09:45that, I'm gonna ask Alexandra
  • 09:47to introduce our speaker.
  • 09:54Okay. Well, welcome to our
  • 09:56first grand rounds and our,
  • 09:59Henry Caban lectureship. It's really
  • 10:01great to see everybody in
  • 10:02this room
  • 10:04to honor
  • 10:05our very own Henry Cabin,
  • 10:06who spent much of his
  • 10:08career
  • 10:09building a premier interventional program
  • 10:11right here at Yale. So
  • 10:13thank you for your
  • 10:14your work, your contributions.
  • 10:16It's just wonderful to see
  • 10:18you.
  • 10:19That said, it gives me
  • 10:21enormous pleasure to introduce our
  • 10:22speaker today, doctor Greg Stone.
  • 10:24So,
  • 10:25Greg is professor of medicine
  • 10:27and population health sciences
  • 10:29at the Icahn School of
  • 10:30Medicine at Mount Sinai in
  • 10:32New York.
  • 10:33And I suspect, I hope,
  • 10:35many of you,
  • 10:37took a quick look at
  • 10:38his amazing CV that was
  • 10:40circulated
  • 10:41with, the invitation to come
  • 10:43here, all six hundred pages
  • 10:47of his CV. So I'm
  • 10:48just gonna tell you, I'm
  • 10:49not gonna,
  • 10:51even begin to try and,
  • 10:54summarize his CV here. It
  • 10:56would take me till tonight.
  • 10:58Simply, I wanna say that
  • 11:00there are very, very few
  • 11:02people
  • 11:02in, our field that have
  • 11:04had the profound impact
  • 11:07that Greg has had on
  • 11:08our guidelines
  • 11:09and the way we practice
  • 11:10cardiovascular medicine today.
  • 11:13His contributions
  • 11:15are nothing less than prolific.
  • 11:17So based on his CV,
  • 11:19he has a hundred and
  • 11:21thirty multicenter
  • 11:23randomized clinical trials
  • 11:26that he has designed and
  • 11:28conducted,
  • 11:29and he has about two
  • 11:31thousand
  • 11:31peer reviewed manuscripts
  • 11:33in the highest impact journals.
  • 11:36It's no small feat.
  • 11:39His trials have changed practice
  • 11:41across virtually every domain of
  • 11:44interventional cardiology.
  • 11:46From acute myocardial infarction, I
  • 11:49had the great privilege in
  • 11:50my early career to be
  • 11:51working with Greg on the
  • 11:53Horizons AMI clinical study,
  • 11:56vulnerable plaque. He's gonna be
  • 11:57talking to us about that
  • 11:59today, but it goes well
  • 12:00beyond that. Antithrombotic
  • 12:02therapy,
  • 12:03drug eluting stents,
  • 12:05invasive imaging,
  • 12:07structural heart disease, mitral valve
  • 12:09disease, and more recently,
  • 12:11heart failure.
  • 12:12And on that note, we're
  • 12:14absolutely privileged to be,
  • 12:16working very closely together with
  • 12:18Greg,
  • 12:19with Catherine and,
  • 12:21Clark and Carlos Mena's leadership
  • 12:24here at Yale
  • 12:25in a, evaluating
  • 12:27a pulmonary denervation
  • 12:29therapy for patients with group
  • 12:31two pulmonary hypertension. We're absolutely
  • 12:34thrilled to be able to
  • 12:35partner with you on that.
  • 12:38I would
  • 12:39characterize Greg as the consummate
  • 12:42academic
  • 12:43clinician.
  • 12:44He's a masterful educator as
  • 12:46we're gonna see and hear.
  • 12:48His knowledge is
  • 12:51nothing less than encyclopedic.
  • 12:53His scientific rigor knows absolutely
  • 12:57no bound,
  • 12:58and he's
  • 12:59got a relentless, and I
  • 13:01mean relentless
  • 13:03attention to detail.
  • 13:05I'm gonna just wrap it
  • 13:07up here. I don't wanna
  • 13:08go on and on, but
  • 13:09I just wanna say a
  • 13:10few personal things. Greg has
  • 13:12been an outstanding
  • 13:14collaborator, mentor, and a dear
  • 13:16friend to myself
  • 13:18and so many in the
  • 13:19field.
  • 13:21And if you think about
  • 13:22it with all the accomplishments
  • 13:25that Greg has had,
  • 13:27he's incredibly generous with his
  • 13:29time. We're thrilled that you're
  • 13:31here today to share your
  • 13:32knowledge and teach our faculty.
  • 13:34And he's just genuinely a
  • 13:36wonderful,
  • 13:37wonderful human being. So please
  • 13:40join me in welcoming
  • 13:41one of the truly
  • 13:43transformative
  • 13:44figures in modern interventional cardiology,
  • 13:47doctor Greg Stone.
  • 13:57Well, thank you, Alexander, for
  • 13:59that beautiful introduction. And, yeah,
  • 14:01Alexander and I go back
  • 14:02a long way, and I'll
  • 14:03I'll just tell everybody here
  • 14:04you're very lucky to have
  • 14:06her here at Yale.
  • 14:07It's also really a pleasure
  • 14:09to be here.
  • 14:10My, daughter recently graduated,
  • 14:12from the School of Public
  • 14:14Health, so I'm
  • 14:15no stranger to this campus.
  • 14:17And, also, while I work
  • 14:19at Mount Sinai Medical Center
  • 14:20in New York City, I
  • 14:21actually live in Greenwich, Connecticut.
  • 14:22So I'm not gonna get
  • 14:23any awards for being the
  • 14:25farthest person who's come away
  • 14:27for this year for your
  • 14:28grand rounds for this talk.
  • 14:30But it's gonna be really
  • 14:31great to speak to you
  • 14:32today about
  • 14:33a new topic. It may
  • 14:34be new to some of
  • 14:35you. Let's see how I
  • 14:37advance here.
  • 14:39Oh, Keith. Okay. Great.
  • 14:41And that's on a a
  • 14:43new area, which is becoming
  • 14:44really on a lot of
  • 14:45people's radar screens,
  • 14:47especially those of us who
  • 14:48are interested in revascularization
  • 14:50therapy. Because as I'm gonna
  • 14:51show you, most of what
  • 14:52we do when we revascularize
  • 14:54patients, either with PCI or
  • 14:56with surgery,
  • 14:57really does not prolong life,
  • 14:59and it does not prevent
  • 15:00myocardial infarctions. It makes people
  • 15:01feel better. But we're probably
  • 15:03not getting the most out
  • 15:05of these approaches. And and
  • 15:06these are, you know, therapies
  • 15:07that are done in up
  • 15:08to a million people a
  • 15:09year in the United States
  • 15:11alone.
  • 15:12And, as I'm gonna show
  • 15:13you, we've really been focusing
  • 15:15on the wrong areas of
  • 15:16the coronary tree, And that's
  • 15:18really hard to believe, but
  • 15:19it's really true. So I'm
  • 15:21gonna talk to you about
  • 15:22today about the detection and
  • 15:23treatment of vulnerable plaque because
  • 15:24that's really where all the
  • 15:26action is.
  • 15:28So
  • 15:29I like to really start
  • 15:30with this slide. This was
  • 15:31an incredible,
  • 15:32article that was written by
  • 15:34Betsy Nabel and Eugene Braunwald
  • 15:36a number of years ago
  • 15:37in the New England Journal,
  • 15:38and they tried to relate
  • 15:40the tremendous
  • 15:41advances that have been made
  • 15:42in reducing case fatality rates
  • 15:44in in patients, with cardiovascular
  • 15:46disease. And you could see
  • 15:47from nineteen fifty to nineteen
  • 15:49seventy, there was a very
  • 15:50high case fatality rate. And
  • 15:52then starting in nineteen seventy
  • 15:53down through about two thousand
  • 15:54and ten, there was this
  • 15:56tremendous steady decline, about a
  • 15:58seventy percent reduction,
  • 16:00in mortality from heart disease.
  • 16:02And they related to several
  • 16:04of the seminal advances.
  • 16:05And and several of these,
  • 16:07obviously relate to prevention,
  • 16:09but several are also due
  • 16:10to the development, first of
  • 16:11cardiac surgery and then of
  • 16:13coronary angioplasty,
  • 16:15and,
  • 16:16then to the treatment of
  • 16:17acute myocardial infarction, first with
  • 16:19thrombolytic therapy and then with,
  • 16:21primary angioplasty.
  • 16:22And so it looks like
  • 16:23this is just a huge
  • 16:25success story for cardiology.
  • 16:27And if you look, where
  • 16:28we really make a difference
  • 16:30is in our treatment in
  • 16:31patients with heart attacks. In
  • 16:33patients with STEMI,
  • 16:35I was telling Eric earlier,
  • 16:37we were involved in the
  • 16:38very first trial, the PAIMI
  • 16:39trial, which is really the
  • 16:40one that, changed things, and
  • 16:42that led to a total
  • 16:43of twenty three randomized trials
  • 16:45of primary PCA
  • 16:46versus thrombolytic therapy in patients
  • 16:48with ST segment elevation MI.
  • 16:50And we showed that we
  • 16:51clearly reduced mortality,
  • 16:53reduced reinfortunes,
  • 16:55eliminate essentially all the hemorrhagic
  • 16:57strokes, so we reduce total
  • 16:59stroke. People go home from
  • 17:00the hospital earlier. They get
  • 17:02better myocardial recovery, etcetera, etcetera.
  • 17:04And that, I don't have
  • 17:05to tell anybody here, has
  • 17:06been probably the biggest success
  • 17:08story and the... Where, as
  • 17:10interventional cardiologists, we can make
  • 17:11the biggest difference in patients'
  • 17:13lives.
  • 17:14The same is true in
  • 17:15non ST segment elevation myocardial
  • 17:17infarction,
  • 17:18where, again, meta analysis have
  • 17:20shown in about eighty four
  • 17:21hundred patients that we reduce
  • 17:22mortality and myocardial infarction.
  • 17:26But still, despite all of
  • 17:27this progress, cardiovascular disease is
  • 17:30still what some would call
  • 17:31a global pandemic.
  • 17:32And this, you know, recent,
  • 17:35compilation in The Lancet shows
  • 17:36that still it is the
  • 17:38number one cause of death
  • 17:40around the world, responsible for
  • 17:42about one third of all
  • 17:44deaths in the, complete world,
  • 17:46with ischemic heart disease being
  • 17:48the number one cause of
  • 17:49death, almost twenty million people
  • 17:51per year.
  • 17:52And if you look at
  • 17:53what's going on in the
  • 17:54United States, actually,
  • 17:56despite all that progress that
  • 17:58we've made, we've kind of
  • 17:59stalled since about nineteen ten.
  • 18:01And from nineteen ten to
  • 18:02nineteen twenty five, the case
  • 18:03fatality rates for heart disease
  • 18:05are pretty flat. And in
  • 18:07fact, given the, increasing age
  • 18:09of the patient population and
  • 18:11the increasing population, the, number
  • 18:13of deaths from cardiovascular disease
  • 18:15are actually increasing.
  • 18:17So we've got a lot
  • 18:18of work to do.
  • 18:21So
  • 18:22as successful as we've been
  • 18:23in treating patients with acute
  • 18:25coronary syndromes,
  • 18:26we don't have the same
  • 18:28impact on patients with chronic
  • 18:29coronary syndromes.
  • 18:31And I'll never forget when,
  • 18:33the presentation of the COURAGE
  • 18:34trial was,
  • 18:36released at the American College
  • 18:37of Cardiology a number of
  • 18:38years ago by Bill Boden,
  • 18:40the first big randomized trial
  • 18:42of twenty two hundred and
  • 18:43seventy patients or so. Chronic
  • 18:45coronary syndromes,
  • 18:46randomized their medical therapy versus
  • 18:48PCI plus medical therapy. Absolutely
  • 18:51no difference in the seven
  • 18:52year rates of death, cardiovascular
  • 18:54death, or myocardial infarction. And
  • 18:56we all thought that something
  • 18:57must have been done wrong,
  • 18:58but it actually wasn't. This
  • 19:00was true. It was then
  • 19:01shown in the,
  • 19:03subsequent berry studies and others.
  • 19:06So we thought, okay. Maybe
  • 19:07the problem was is that
  • 19:08they're not enrolling high enough
  • 19:10risk patients Because a lot
  • 19:11of the patients didn't have
  • 19:13ischemia in these trials, they
  • 19:14just had anatomic disease.
  • 19:16And, I had trained at
  • 19:17Cedars Sinai Medical Center in
  • 19:19Los Angeles for my general
  • 19:20fellowship,
  • 19:21and there was, this is
  • 19:23one paper that... That's been
  • 19:25probably quoted and downloaded ten
  • 19:27thousand times.
  • 19:28And in a non randomized
  • 19:29fashion,
  • 19:30they showed a relationship between
  • 19:32the extent of quantitative ischemia
  • 19:35of the left ventricle and
  • 19:36outcomes.
  • 19:37The more,
  • 19:38myocardial ischemia there was, the
  • 19:40greater the rates of myocardial
  • 19:41infarction and cardiovascular death. And
  • 19:43if patients who happened in
  • 19:44a nonrandomized
  • 19:45fashion to have gotten revascularization
  • 19:47therapy compared to medical therapy,
  • 19:49it seemed like the more
  • 19:50ischemia you had, the better
  • 19:52the response to revascularization.
  • 19:54And when you got to
  • 19:55about ten percent of the
  • 19:57ventricle being ischemic, that seemed
  • 19:59to be where revascularization,
  • 20:01had a big advantage.
  • 20:03So that led us to
  • 20:04design the ischemia trial. And
  • 20:06I was one of the
  • 20:07co principal investigators along with
  • 20:08Bob Harrington and, of course,
  • 20:10Judy Hochman and Dave Marron.
  • 20:12And we said, okay. Let's
  • 20:13take chronic coronary syndromes,
  • 20:15patients with at least ten
  • 20:17percent myocardial ischemia,
  • 20:19but who don't have a
  • 20:20lot of symptoms, so they're
  • 20:21not gonna all cross over.
  • 20:23And let's randomize those patients
  • 20:25to,
  • 20:26either an angiographic strategy followed
  • 20:28by revascularization
  • 20:29with either PCI or CABG
  • 20:31is appropriate, versus just conservative
  • 20:33care, where you don't even
  • 20:34do an angiogram. You don't
  • 20:35even have to know what
  • 20:36the coronary anatomy is.
  • 20:38And this, of course, was
  • 20:40the result of the ischemia
  • 20:41trial, and this is very
  • 20:42contemporary.
  • 20:43And there was no overall
  • 20:45reduction in cardiovascular
  • 20:46death or myocardial infarction.
  • 20:49There was a slight early
  • 20:50risk of doing the procedures,
  • 20:52not bad, but a little
  • 20:53bit of an early risk.
  • 20:54There was a little bit
  • 20:55of a late benefit perhaps,
  • 20:57but overall, no significant difference
  • 21:00with follow-up to five years.
  • 21:01And at the this year,
  • 21:03we'll report the absolute final
  • 21:05ten year, what we call
  • 21:06ischemic extend follow-up,
  • 21:08in this,
  • 21:09trial as a late breaker.
  • 21:12Now don't get me wrong.
  • 21:14We do make people feel
  • 21:15better
  • 21:16by revascularizing
  • 21:17with chronic coronary syndrome.
  • 21:19And, the major secondary endpoint
  • 21:21in this trial was the
  • 21:22relief of angina,
  • 21:23and I could show you
  • 21:24this data cut in many,
  • 21:25many ways. But there's a
  • 21:27marked reduction in angina, either
  • 21:29the absolute level of angina
  • 21:30or becoming angina free and
  • 21:32improve quality of life as
  • 21:33measured by the SACS score
  • 21:34in others. So we make
  • 21:36people feel better. And the
  • 21:37the patients who are having
  • 21:38symptoms, the more symptoms they
  • 21:40have, the more we're gonna
  • 21:40make them feel better. But
  • 21:42we don't make them live
  • 21:43longer, and we don't prevent
  • 21:45myocardial infarctions.
  • 21:46And that's hard for,
  • 21:48many general cardiologists, let alone
  • 21:50interventionalists and cardiac surgeons to
  • 21:52accept.
  • 21:53There may be some exceptions,
  • 21:55perhaps high grade left main
  • 21:56disease. The old data suggested
  • 21:58that, yes, surgery makes a
  • 22:00difference there. Perhaps extensive disease
  • 22:00with
  • 22:03extensive disease with proximal AD
  • 22:04involvement, but we don't even
  • 22:05have great data on that
  • 22:06to suggest that we're improving
  • 22:08prognosis.
  • 22:10And the reason, I think,
  • 22:12is that we're really focusing
  • 22:14on the wrong parts of
  • 22:15the coronary tree.
  • 22:17So this is the typical
  • 22:18type of lesion that we're
  • 22:19revascularizing
  • 22:20in patients with chronic coronary
  • 22:22syndromes. You see a long
  • 22:23seventy five, eighty percent stenosis
  • 22:25in the right coronary artery,
  • 22:27and this is enough to
  • 22:29invoke exercise induced ischemia so
  • 22:31the patients will have angina,
  • 22:33and dyspnea exertion, etcetera.
  • 22:35But when you look at
  • 22:36this lesion, pathologically,
  • 22:38you see what's called... What
  • 22:40I call garden variety atherosclerosis,
  • 22:42which is pathologic interval thickening.
  • 22:44Okay. This is a very
  • 22:45stable, often fibrotic lesion,
  • 22:48and it will, yes, constrict
  • 22:50the lumen and therefore restrict
  • 22:52blood flow,
  • 22:54during stress or exercise,
  • 22:56but it rarely goes on
  • 22:58to fissure or thrombose and
  • 23:00cause a myocardial infarction. This
  • 23:02lesion could be stable for
  • 23:03forty years.
  • 23:06So I really got interested
  • 23:07in this field from a
  • 23:08study that came out,
  • 23:10several decades ago,
  • 23:12from the NHLBI
  • 23:13dynamic registry.
  • 23:15And they first published on
  • 23:17thirty seven hundred patients that
  • 23:18underwent PCI,
  • 23:20and they actually
  • 23:21found that six percent of
  • 23:22those patients
  • 23:24within one year
  • 23:26developed an acute coronary syndrome,
  • 23:28mostly acute myocardial infarction,
  • 23:30at sites that were remote
  • 23:32from any area that was
  • 23:33intervened on. And this is,
  • 23:35again, not such a great
  • 23:36image, but from the original
  • 23:37publication.
  • 23:39A right coronary artery, and
  • 23:40you can see very mild
  • 23:41diffuse disease in the right.
  • 23:43And that within one year,
  • 23:44there's a new subtotal stenosis
  • 23:46in that right coronary artery.
  • 23:48And the mean plaque progression
  • 23:50went very quickly from forty
  • 23:51two percent to eighty four
  • 23:52percent angiographically at a mean
  • 23:54of five point two months.
  • 23:56And this was kind of
  • 23:57termed a vulnerable plaque. That
  • 23:59is a plaque that you
  • 24:00don't... Maybe not appreciate that
  • 24:02it's such a severe lesion,
  • 24:03but but it's the kind
  • 24:04of lesion that places the
  • 24:05patients at risk for future
  • 24:07cardiovascular events.
  • 24:09And there were multiple studies
  • 24:10that then came out that
  • 24:11showed that these plaques are...
  • 24:13That that had a serial
  • 24:14angiograms and showed that these
  • 24:16plaques are very mild appearing
  • 24:17angiographically.
  • 24:18They're never the kind of
  • 24:20plaques that we would do
  • 24:20PCI on, and the surgeons
  • 24:22would never bypass these kind
  • 24:23of plaques. But the majority
  • 24:25that that then close, they
  • 24:27usually thrombose, and they either
  • 24:29get a subtotal or a
  • 24:30total occlusion,
  • 24:32cause either sudden cardiac death,
  • 24:33a STEMI or a non
  • 24:35STEMI. Again, they go from
  • 24:37very, very mild to very
  • 24:39severe, very suddenly.
  • 24:41So
  • 24:42most of these plaques, when
  • 24:44you look at them pathologically,
  • 24:46are so called tikfas,
  • 24:48thin capped fibroatheromas.
  • 24:51And in contrast to that
  • 24:52last pathologic image I showed
  • 24:54you, these look very, very
  • 24:55different. They have this very
  • 24:57well formed necrotic core, which
  • 24:59consists of cholesterol, cholesterol esters,
  • 25:02and inflammatory
  • 25:03cells, macrophages, and t lymphocytes.
  • 25:05And there's a very thin
  • 25:07fibrous cap separating this necrotic
  • 25:09core from the lumen. And
  • 25:11that thin fibers cap is
  • 25:12very metabolically active. It's,
  • 25:15infiltrated with macrophages.
  • 25:16And when matrix metalloproteinases
  • 25:19and other digestive enzymes get
  • 25:20released, that fibrous cap can
  • 25:22rupture.
  • 25:23And that leads the necrotic
  • 25:24cord to release its very
  • 25:26prothrombotic
  • 25:26contents, including tissue factor, and
  • 25:29you suddenly
  • 25:30can get a thrombotic occlusion.
  • 25:32Now in this case, I
  • 25:33showed you a tiktva, which
  • 25:35was relatively obstructive.
  • 25:36And some of these tiktva
  • 25:37are obstructive,
  • 25:39but probably about sixty percent
  • 25:40of them are like this.
  • 25:42Okay? They've got really a
  • 25:43well preserved lumen, but there's
  • 25:45this little time bomb sitting
  • 25:47here with this, again, well
  • 25:49formed necrotic
  • 25:50core,
  • 25:51which which has outward pressure.
  • 25:52There's a lot of hemostatic
  • 25:54forces going on here. And,
  • 25:55again, metabolically active thin fibers
  • 25:57cap ruptures, and then in
  • 25:58the mat... In a matter
  • 25:59of minutes,
  • 26:01you can then get this
  • 26:02massive thrombotic occlusion.
  • 26:04So, again,
  • 26:05patient, you know, it's like
  • 26:06a normal EKG. They've got
  • 26:08no idea that they've got
  • 26:09this type of lesion.
  • 26:10Probably
  • 26:11two thirds or three quarters
  • 26:12of you have coronary disease,
  • 26:14and, hopefully,
  • 26:15relatively few of you have
  • 26:17thin cap fibroatheromas.
  • 26:18You just got more of
  • 26:19that garden variety, either fibrocalcific
  • 26:22or fibrotic,
  • 26:24disease.
  • 26:24But some will have these
  • 26:26tiktvas, and these are the
  • 26:27ones that cause the trouble.
  • 26:31And we always... In the
  • 26:32volatile plaque field, we make
  • 26:33the analogy that these are
  • 26:35like volcanoes.
  • 26:36Because when you look at
  • 26:37these from a cross sectional
  • 26:38point of view, this is
  • 26:39kind of what they look
  • 26:40like. You can see the
  • 26:41well formed necrotic core with
  • 26:42the... You can see the
  • 26:43cholesterol clefts.
  • 26:45And then you can see
  • 26:46right at the tip, there's
  • 26:47this very thin fibrous cap,
  • 26:48and it's just, you know,
  • 26:49waiting to rupture. But you
  • 26:51can't tell. Before that, it's
  • 26:52a dormant volcano. You have
  • 26:54no idea when a volcano
  • 26:55is gonna go
  • 26:57off. Or maybe we can
  • 26:58figure out when it's gonna
  • 27:00go off. Maybe we can
  • 27:01at least identify
  • 27:03the morphology and the biochemistry
  • 27:05of that plaque compared to
  • 27:07the other plaques that I
  • 27:08showed you.
  • 27:09And, I'm not gonna spend...
  • 27:10I could spend an hour
  • 27:11talking about this aspect of
  • 27:13it, but with intravascular imaging,
  • 27:15starting with grayscale IVUS, then
  • 27:17moving to VH IVUS, which
  • 27:19is a radio frequency IVUS,
  • 27:21where we can color code
  • 27:22the different types of plaques,
  • 27:24going to optical coherence tomography,
  • 27:26and, NIRS infrared spectroscopy, which
  • 27:29is a way of looking
  • 27:30at the chemistry of the
  • 27:31plaque,
  • 27:31we can,
  • 27:33basically differentiate the five types
  • 27:35of plaques
  • 27:36by their pictures that we
  • 27:38can create. And this is
  • 27:39a classification that Renu Vermani,
  • 27:41probably the most well known
  • 27:42cardiac pathologist, came up with.
  • 27:44We can differentiate these plaques
  • 27:46from fibrocalcific
  • 27:47to fibrous to pathological gable
  • 27:49thickening,
  • 27:50and then the fibroatheromas.
  • 27:51They're the ones that have
  • 27:52that well formed necrotic core.
  • 27:54And if there's a thick
  • 27:56cap, that's a thick cap
  • 27:57fibroatheromat.
  • 27:58And if there's a thin
  • 27:59cap, which is usually less
  • 28:00than about sixty five microns,
  • 28:02that's a ticfah. And those
  • 28:04are the ones that are
  • 28:05really the highest risk.
  • 28:08So a number of years
  • 28:09ago, we came up with
  • 28:10an idea to see if
  • 28:12we could actually prospectively
  • 28:14identify these lesions using intravascular
  • 28:16imaging. We know that you
  • 28:18couldn't do it by angiography.
  • 28:19You couldn't do it by
  • 28:20any noninvasive,
  • 28:21technique. And, again, most of
  • 28:23these lesions are not flow
  • 28:25limiting, so they're not hemodynamically
  • 28:26obstructive. They look mild on
  • 28:28the angiogram.
  • 28:29So we did a study,
  • 28:31called the prospect study. And
  • 28:33I worked with Alexandra on
  • 28:34this, and now I'm gonna
  • 28:35divert... Digress for a second
  • 28:36and tell a story about
  • 28:38Alexandra
  • 28:39because I said, so here's
  • 28:40what I wanna do. I
  • 28:41wanna do a study
  • 28:42where we're gonna take about
  • 28:43a thousand patients or so,
  • 28:45and we're gonna do,
  • 28:47a three vessel angiograms, and
  • 28:49we're gonna do three vessel
  • 28:50intravascular imaging. Okay?
  • 28:53And Alexander was the director
  • 28:54of the angiographic core laboratory
  • 28:56at the Cardiovascular Research Foundation,
  • 28:57and I said, we wanna
  • 28:58get you these films. And
  • 28:59I don't want you to
  • 29:00look at the lesions. I
  • 29:01want you to look at
  • 29:02every single millimeter of the
  • 29:03coronary tree
  • 29:05and do QCA of every
  • 29:06single millimeter of the coronary
  • 29:08tree. And she said, you
  • 29:09know, Greg, that... That's ridiculous.
  • 29:11That can't be done. That
  • 29:12would take a technician days
  • 29:14to do that. And I
  • 29:15said, we can do it.
  • 29:16I want you to do
  • 29:17it. Will you do it?
  • 29:18And so she agreed.
  • 29:19And then in the intravascular
  • 29:21imaging laboratory where we had,
  • 29:23the director was Akiko Mahara,
  • 29:26we said, Akiko, you have
  • 29:27to go through this, you
  • 29:28know, every frame by frame,
  • 29:30and you have to analyze
  • 29:31every single frame of the
  • 29:32coronary tree.
  • 29:34And then we would, at
  • 29:35baseline,
  • 29:36prospectively
  • 29:37categorize
  • 29:38every single bit of atherosclerosis
  • 29:41in the main three epicardial
  • 29:42coronary arteries, and we'd watch
  • 29:43what happened over the next
  • 29:44three to four years. So
  • 29:45let me show you how
  • 29:46this would work.
  • 29:48So this is a patient
  • 29:49who came in with an
  • 29:51occluded proximal LAD. So we
  • 29:53took patients with acute coronary
  • 29:55syndromes for this study,
  • 29:56and the LAD gets treated
  • 29:58and, with a successful result
  • 30:00than any other high grade
  • 30:01lesions. And then we do
  • 30:03three vessel imaging
  • 30:04of the left main, the
  • 30:05LAD, the circumflex in the
  • 30:07right coronary artery, the main
  • 30:08epicardial branches... Vessels and any
  • 30:10major branches.
  • 30:12So here, I'm gonna show
  • 30:13you is a circumflex.
  • 30:15So ignore the occluded LED.
  • 30:17That got revascularized. It looked
  • 30:18great. And that... The LED
  • 30:20did fine. But here's a
  • 30:21circumflex.
  • 30:22And I'm gonna tell you
  • 30:23that this was done, you
  • 30:25can see, in February of
  • 30:26two thousand and six. And
  • 30:27I'm gonna tell you that
  • 30:28fifty one weeks later, this
  • 30:30patient presented with a non
  • 30:32STEMI due to a lesion
  • 30:34in this circumflex.
  • 30:35And so I'm gonna ask
  • 30:36you, which lesion do you
  • 30:38think caused it? Do you
  • 30:40think your eye immediately gonna
  • 30:41go to this forty percent
  • 30:43stenosis in the mid in
  • 30:44the mid circ? So, you
  • 30:46know, who thinks it might
  • 30:47have been proximal to that
  • 30:49lesion somewhere in the proximal
  • 30:50circ
  • 30:51that caused a non STEMI
  • 30:53within a year?
  • 30:55Nobody.
  • 30:56Maybe one or two. Who
  • 30:57thinks it's gonna be the
  • 30:59forty percent stenosis, the focal
  • 31:00stenosis in the mid circ?
  • 31:03Okay.
  • 31:04Okay?
  • 31:06Who thinks it's gonna be
  • 31:07somewhere
  • 31:09after that forty percent stenosis,
  • 31:10that little lumpy, bumpy area?
  • 31:12Here, we've got three or
  • 31:13four. Who thinks it's gonna
  • 31:14be one of those two
  • 31:15branches, those two distal marginal
  • 31:18branches?
  • 31:19Hard to know. Well, here's
  • 31:20what happened. Okay?
  • 31:22So here is now,
  • 31:24almost exactly a year later,
  • 31:25fifty one weeks later, and
  • 31:26you could see there's a
  • 31:27new thrombotic,
  • 31:29rupture
  • 31:30of that lesion. The forty
  • 31:31percent stenosis hasn't changed at
  • 31:33all. So that was at
  • 31:34that site of that arrow
  • 31:35at what looks like about
  • 31:36an angiographic twenty percent stenosis.
  • 31:39So what we had done
  • 31:40is we had imaged that
  • 31:42whole circumflex and the LAD
  • 31:44and the right coronary artery
  • 31:45at baseline. So now we
  • 31:46go back to baseline, and
  • 31:47let's look at the way
  • 31:48the atherosclerosis
  • 31:50looked like in that circumflex.
  • 31:52And here is basically what
  • 31:53it looked like.
  • 31:54This was a technique called,
  • 31:56radiofrequency
  • 31:57IVUS where, again, we could
  • 31:58color code the different plaques,
  • 32:00and the red is the
  • 32:01kind of plaque that we
  • 32:02worried about. And so we
  • 32:03pull back
  • 32:04from that asterisk, in this
  • 32:06case, all the way up
  • 32:07to the left main,
  • 32:08and the, imaging actually found
  • 32:11three different lesions. And those
  • 32:13little,
  • 32:14three peaks are three different
  • 32:15lesions as the plaque is
  • 32:16getting more severe.
  • 32:18So if we just focus
  • 32:19at site one, which is
  • 32:20where the plaque was that
  • 32:22caused the problem,
  • 32:23each of those frames at
  • 32:24the bottom are every about
  • 32:26five hundred microns
  • 32:28through that, plaque. And the
  • 32:30first thing you could see
  • 32:31from the gray scale at
  • 32:32the bottom is this was
  • 32:33a big bulky plaque.
  • 32:35Okay? Even though it looks
  • 32:36angiographically
  • 32:37like a twenty percent stenosis,
  • 32:39it was actually seventy six
  • 32:40percent
  • 32:41of that lumen was full
  • 32:42of plaque.
  • 32:43And it just shows you
  • 32:44the angiogram is a terrible
  • 32:46discriminator
  • 32:47of how much atherosclerosis
  • 32:48there was. So a huge
  • 32:49amount of atherosclerosis.
  • 32:51So you could see by
  • 32:52QCA from Alexander's lab, the
  • 32:54reference vessel diameter is two
  • 32:55point eight two millimeters. It
  • 32:56was a twenty eight point
  • 32:57six percent stenosis.
  • 32:59It was six point eight
  • 33:00millimeter long lesion at that
  • 33:01site. But by VHIVUS,
  • 33:04it had a seventy six
  • 33:05percent plaque burden. The middle
  • 33:07luminal area was five point
  • 33:08three millimeter squared, which is
  • 33:10not usually obstructive,
  • 33:11and it was coded as
  • 33:12a core lab as a
  • 33:13thick capped fibroatheroma.
  • 33:16So that was this lesion.
  • 33:18So what we did was
  • 33:19we did this in about
  • 33:21seven hundred patients, and we
  • 33:22characterized thirty six hundred lesions
  • 33:24in the coronary tree. A
  • 33:26lesion had to have at
  • 33:27least a forty percent placard.
  • 33:29And then we looked to
  • 33:30see what kind of lesions
  • 33:32were causing future events.
  • 33:34And our hypothesis was, based
  • 33:36on what Vermani had taught
  • 33:37us, is that the tikvas
  • 33:38would be the highest risk,
  • 33:40then the thick cap fibroatheromas
  • 33:42would be the intermediate risk,
  • 33:44and all the other lesions
  • 33:45would have almost no risk.
  • 33:48So the first thing that
  • 33:49we learned
  • 33:50was that the number one
  • 33:51predictor of events was the
  • 33:53amount of plaque that was
  • 33:54there. And as you could
  • 33:55see,
  • 33:57if you had greater than
  • 33:58seventy percent plaque burden,
  • 34:00in a lesion that looked
  • 34:01angiographically
  • 34:02mild on the right side
  • 34:03of the, graph,
  • 34:05each of those lesions, and
  • 34:06these are lesion specific event
  • 34:08rates within a median follow-up
  • 34:10of three point two years,
  • 34:11had a nine point five
  • 34:13percent event rate of causing
  • 34:14an acute coronary syndrome, either
  • 34:16new unstable angina
  • 34:18requiring hospitalization,
  • 34:20myocardial infarction,
  • 34:21or attributed,
  • 34:22cardiac death.
  • 34:24If it was a sixty
  • 34:24to seventy percent stenosis,
  • 34:26those lesions had about a
  • 34:27two point five percent event
  • 34:29rate. And then you could
  • 34:30see if you get below
  • 34:31that... In fact, when you
  • 34:32get to below forty percent,
  • 34:33we didn't even call those
  • 34:34lesions.
  • 34:35Okay? And there were thousands,
  • 34:37probably tens of thousands of
  • 34:39those, and not a single
  • 34:41site that had less than
  • 34:42forty percent plaque caused an
  • 34:44event within about three to
  • 34:46four year follow-up.
  • 34:48So the first thing that
  • 34:49came out of prospect was,
  • 34:51the me... On the mean
  • 34:52baseline diameter stenosis of those
  • 34:54lesions by QCA was thirty
  • 34:55two percent. So by the
  • 34:57angiogram, these things look trivial,
  • 34:59and that's why we don't
  • 35:00treat them. But these are
  • 35:01the ones that are causing,
  • 35:03unstable angina heart attacks and
  • 35:05cardiac death.
  • 35:07So the first thing that
  • 35:07we did was explode
  • 35:09a major myth that was
  • 35:11prevalent in cardiology at that
  • 35:12time.
  • 35:13And that was that vulnerable
  • 35:15plaques, the ones that place
  • 35:16the patients at risk, are
  • 35:18not mild. They're actually very
  • 35:20severe, but they just look
  • 35:21mild angiographically.
  • 35:23So you have to stop
  • 35:24relying on the angiogram.
  • 35:26And as an interventional cardiologist,
  • 35:28I'm in love with the
  • 35:29angiogram,
  • 35:29but for this purpose, it
  • 35:31doesn't tell us what we
  • 35:32need to know.
  • 35:35However,
  • 35:36plaque is not enough.
  • 35:37Okay? Because there's stable plaque,
  • 35:40like that pathological interval thickening
  • 35:42that I showed you early
  • 35:43on, and then there is
  • 35:44the kind of vulnerable plaque.
  • 35:46And
  • 35:47I was as surprised as
  • 35:49anybody
  • 35:50to see that the hypothesis
  • 35:51worked out. And this paper
  • 35:53was published in the New
  • 35:54England Journal and, was kind
  • 35:56of revolutionary in its time.
  • 35:58But you could see here
  • 35:59that if we had a
  • 36:00large plaque burden with a
  • 36:02thin cap fibroatheroma
  • 36:04as prospectively identified,
  • 36:06it had a sixteen percent
  • 36:07likelihood that one lesion
  • 36:09of causing a major event
  • 36:10within three years.
  • 36:12If it was a thick
  • 36:12cap fibroatheroma,
  • 36:14it had an intermediate risk,
  • 36:16eight point seven percent. And
  • 36:17if it was any of
  • 36:18the other types that we
  • 36:19thought were gonna be stable,
  • 36:21they were really stable. And
  • 36:22in fact, even though there
  • 36:23was a lot of plaque,
  • 36:24it conferred no extra risk
  • 36:26whatsoever. Again, it might have
  • 36:27caused angina,
  • 36:28but it didn't cause any
  • 36:30risk of a cardiovascular death
  • 36:31or myocardial infarction.
  • 36:34We then went on and
  • 36:35we did subsequently a study
  • 36:37called prospect two,
  • 36:38which was a similar type
  • 36:39of prospective natural history multimodality
  • 36:42imaging study, very similar. But
  • 36:44instead of using radio frequency
  • 36:46IVS, we used near infrared
  • 36:47spectroscopy
  • 36:48and IVUS. And near infrared
  • 36:50spectroscopy
  • 36:51is when it was approved
  • 36:52by the FDA,
  • 36:53was,
  • 36:54touted as the most accurate
  • 36:56spectroscopic
  • 36:57technique to identify any tissue
  • 36:59type in the body. And,
  • 37:00basically, it's very simple. It
  • 37:02basically looks up and down
  • 37:03the artery, and yellow is
  • 37:05lipid, okay, cholesterol
  • 37:07and cholesterol esters, and red
  • 37:09is not. And the wavy
  • 37:10black thing is wire artifact.
  • 37:12And so here is a
  • 37:14example from prospect two,
  • 37:16where you can see this
  • 37:17was a right coronary artery.
  • 37:18There was... It was intervened
  • 37:20on where it says culprit
  • 37:21stent in the distal right,
  • 37:22and then we imaged the
  • 37:23entire right coronary artery.
  • 37:25Here, we did fractional flow
  • 37:27reserve in this study to
  • 37:28prove that all of these
  • 37:29were physiologically non significant lesions.
  • 37:31The FFR was normal, point
  • 37:32nine four.
  • 37:33And here you can see
  • 37:35I point to the arrow
  • 37:37where what happened here,
  • 37:39at,
  • 37:40about three years later is
  • 37:42that that lesion, which was
  • 37:43about twenty percent at baseline,
  • 37:45suddenly became ninety five percent
  • 37:47and caused a,
  • 37:49a non sigma elevation myocardial
  • 37:51infarction. And then if you
  • 37:52go back to the baseline,
  • 37:53what you can see
  • 37:55is up and down, if
  • 37:56you look at the red
  • 37:57carpet, up and down that
  • 37:58vessel, this is the whole
  • 38:00vessel splayed out longitudinally.
  • 38:02There's almost no lipid in
  • 38:04the vessel exactly at where
  • 38:05that big arrow is.
  • 38:07And if you notice the
  • 38:08rest of the vessel, nothing
  • 38:10happens to the rest of
  • 38:10the vessel three years later.
  • 38:12But that area is the
  • 38:14place that ruptures and then
  • 38:15thrombosis.
  • 38:16And then when you look
  • 38:17at it and you superimpose
  • 38:18the IVUS at baseline,
  • 38:20you can see that the
  • 38:21plaque burden was eighty percent
  • 38:22at that lesion.
  • 38:24So huge positive remodeled vessel
  • 38:26with a lot of plaque,
  • 38:27which was very, very lepidic,
  • 38:30and, that's a vulnerable plaque.
  • 38:33So in this study, we
  • 38:34coined the term a two
  • 38:36feature vulnerable plaque, which is
  • 38:38one, a lot of plaque
  • 38:39burden, greater than seventy percent
  • 38:40stenotic,
  • 38:41and in this case, with
  • 38:43high lipid content.
  • 38:45And when you have both
  • 38:46of those features present, you
  • 38:47need both, and then you've
  • 38:49got a high risk plaque.
  • 38:53Finally,
  • 38:53others people, not us, but
  • 38:55other people did studies with
  • 38:56optical coherence tomography, and this
  • 38:58is the only technique. It's
  • 38:59it's like intravascular ultrasound,
  • 39:01but using laser light, so
  • 39:03it's got a much higher
  • 39:04resolution of ten to twenty
  • 39:05microns. And it's the only
  • 39:06technique where you can really
  • 39:08see the thickness of the
  • 39:09fibrous cap. The only one
  • 39:10where you can really say
  • 39:11is it less than or
  • 39:12greater than sixty five microns.
  • 39:14And sure enough, when they
  • 39:15define a thin cap fibroatheroma
  • 39:18with a thin fibrous cap
  • 39:19and a large lipid arc,
  • 39:21then you distinguish which lesions,
  • 39:23in this case, the study
  • 39:25combined,
  • 39:26trial
  • 39:27showed which lesions were the
  • 39:29high risk lesions.
  • 39:31So all of this gets
  • 39:33put into multivariable analysis to
  • 39:35see if it really, hangs
  • 39:36out, And it turns out
  • 39:37none of the clinical features
  • 39:39predict this, none of the
  • 39:40angiographic features predict this, but
  • 39:42intravascular imaging predicts it. And
  • 39:44you can see the three
  • 39:45largest studies, PROSPECT one, PROSPECT
  • 39:47two, and then, JANG, which
  • 39:49was a large OCT study.
  • 39:51And you can see what
  • 39:51the big predictors are. Are.
  • 39:53It's plaque burden greater than
  • 39:54seventy percent.
  • 39:55It is a thin cap
  • 39:57fibroethronoma
  • 39:58by either,
  • 39:59virtual histology
  • 40:01or by OCT.
  • 40:02And then it is,
  • 40:04a large lipid content by
  • 40:06near infrared spectroscopy.
  • 40:08Minimal luminal area being small
  • 40:10has been kind of a
  • 40:11borderline predictor, but it's probably
  • 40:13not as important as the
  • 40:15others.
  • 40:17So can we identify vulnerable
  • 40:18plaque? We have answered that
  • 40:20question definitively.
  • 40:22The answer is yes. There
  • 40:23have now been nine
  • 40:25prospective
  • 40:25studies like this that, based
  • 40:27on, what Alexandra and I
  • 40:29did in Prospect one, and
  • 40:30that's now become the standard
  • 40:32methodology to do it,
  • 40:34that have shown that radio
  • 40:35frequency IVUS, NEARS IVUS, OCT,
  • 40:38and, yes, probably
  • 40:39noninvasively
  • 40:40with CTA, that could be
  • 40:41a whole another lecture, can
  • 40:43identify non full limiting plaques
  • 40:45that place patients at risk
  • 40:46for future events.
  • 40:48Okay.
  • 40:49So you've gotta see beyond
  • 40:51the angiogram. You gotta take
  • 40:52that NHLBI
  • 40:53dynamic lesion, which you can't
  • 40:55tell. Is it a stable
  • 40:56atherosclerotic
  • 40:57plaque,
  • 40:58inactive, noninflamed,
  • 41:00or is it a vulnerable
  • 41:03atherosclerotic
  • 41:03plaque, which is active and
  • 41:05inflamed and has this thin
  • 41:06fibers cap and necrotic core?
  • 41:08And now we do have
  • 41:09imaging techniques that can clearly
  • 41:11differentiate those if we go
  • 41:13to the trouble of doing
  • 41:14it. So why would we
  • 41:15wanna go to the trouble
  • 41:16of doing it? It will
  • 41:17be nice to tell people
  • 41:18their prognosis,
  • 41:19but, obviously, we'd like to
  • 41:21affect it.
  • 41:22So what do we do
  • 41:23about this? Okay? Here's a
  • 41:25sixty eight year old diabetic
  • 41:26woman with atypical angina who
  • 41:29was treated with aspirin and
  • 41:30atorvastatin,
  • 41:31and because she had atypical
  • 41:32angina, she ended up getting
  • 41:34cathed, and she had whistle
  • 41:35clean coronaries
  • 41:36except for this mid LAD
  • 41:38lesion, maybe a twenty, twenty
  • 41:40five percent stenosis.
  • 41:42So she had atypical angina,
  • 41:44so let's do a fractional
  • 41:45flow reserve. And her fractional
  • 41:47flow reserve is point eight
  • 41:48eight normal. Right? Above point
  • 41:50eight zero is normal.
  • 41:51So... Okay.
  • 41:53Mild stenosis,
  • 41:55nonobstructive
  • 41:56disease, probably not angina.
  • 41:58So we'll just go ahead
  • 41:59and treat her. And what
  • 42:01happens?
  • 42:02Three months later, she thrombosis,
  • 42:04that thirty percent stenosis. And
  • 42:06at that time, the doc
  • 42:07cited, oh, what's going on
  • 42:09here? I'm gonna image it.
  • 42:10And now he image it.
  • 42:11He first aspirates the thrombus,
  • 42:12and then he images it.
  • 42:13And here he sees... This
  • 42:15is the OCT image showing
  • 42:16three hundred and sixty degrees
  • 42:18of lipid, a thin ruptured
  • 42:19fibrous cap.
  • 42:21So if that was detected
  • 42:23at that thirty percent
  • 42:24point, maybe we could have
  • 42:26put that patient on a
  • 42:27PCSK nine inhibitor. Maybe we
  • 42:29could have drove her LDL
  • 42:30down to twenty. Maybe we
  • 42:31could have done PCI. Maybe
  • 42:33she should have gotten a
  • 42:33LIMA. Could something have prevented
  • 42:35that that we're not doing
  • 42:36today?
  • 42:38Here's another case. Here's a,
  • 42:40patient who presented with unstable
  • 42:42angina, a fifty seven year
  • 42:43old woman. She had a,
  • 42:44you know, subtotal stenosis,
  • 42:47in the mid right coronary
  • 42:48artery. Then there's another thirty
  • 42:51percent stenosis. So should that
  • 42:52be treated or not? Well,
  • 42:54in this case, the doc
  • 42:55actually did,
  • 42:57intravascular ultrasound with near infrared
  • 42:59spectroscopy,
  • 43:00and here's what they found.
  • 43:02They found that both of
  • 43:04those lesions, the culprit lesion,
  • 43:05which is the blue arrow,
  • 43:06and that thirty percent stenosis
  • 43:09was a lipid rich plaque.
  • 43:11So he actually said, well,
  • 43:12look. I'm gonna stent that
  • 43:13mid lesion anyway, so why
  • 43:14don't I just use a
  • 43:15longer stent and let me
  • 43:17cover that, a vulnerable plaque
  • 43:19more distally? That's not exactly
  • 43:21in the guidelines, but I
  • 43:22think it's reasonable to do
  • 43:24rather than ending a stent
  • 43:25very close to it. So
  • 43:26he did that,
  • 43:28and,
  • 43:29you know, here's what he
  • 43:30got. It looks like a
  • 43:32beautiful result, and you could
  • 43:33see the near infrared spectroscopy
  • 43:35after the stent. There's a
  • 43:36little bit of lipid left,
  • 43:37but not much. We often
  • 43:38actually embolize a lot of
  • 43:40lipid during these procedures.
  • 43:42But what he didn't notice
  • 43:43or didn't pay attention to
  • 43:45was this other lesion that
  • 43:46I got a bracket around
  • 43:47at the distal right coronary
  • 43:48artery. And it was about
  • 43:50a twenty, thirty percent stenosis,
  • 43:52but he didn't image down
  • 43:53that far. And he just
  • 43:54left that alone. But I'm
  • 43:56sorry. He didn't image down
  • 43:57that far initially, but he
  • 43:58did image down that far
  • 44:00on the second procedure. And
  • 44:01here you could see the
  • 44:02square to the right at
  • 44:03the bottom, and that is
  • 44:04an intensely lepidic plaque,
  • 44:07but he didn't wanna get
  • 44:08into that. We don't have
  • 44:09any indication today to treat
  • 44:10these non flow limiting vulnerable
  • 44:12plaques, so he left it
  • 44:13alone. And so five years
  • 44:15later,
  • 44:16the patient comes in with
  • 44:17an inferior STEMI
  • 44:19due to a rupture of
  • 44:20that plaque.
  • 44:22So this happens again and
  • 44:23again and again.
  • 44:26So can we improve the
  • 44:27outcomes of what we're doing?
  • 44:28I'll tell you why I
  • 44:29really do believe
  • 44:30we can.
  • 44:32You take a trial like
  • 44:33the complete trial,
  • 44:34and many of you remember
  • 44:36this. This was four thousand
  • 44:37STEMI patients with multivessel disease,
  • 44:40where you treat the infarct
  • 44:41artery, of course, and then
  • 44:43they randomized patients to treat
  • 44:45all the other seventy percent
  • 44:46stenoses,
  • 44:47just prophylactically
  • 44:48versus leaving them alone and
  • 44:50treating them medically. And this
  • 44:51was a markedly positive trial.
  • 44:53It showed a reduction in
  • 44:54cardiovascular death and new myocardial
  • 44:56infarction, particularly
  • 44:57reducing MI, unstable angina, and
  • 45:00and unplanned revascularization.
  • 45:02And because of this and
  • 45:03other smaller trials, this is
  • 45:05now class one a in
  • 45:06the guidelines. This is how
  • 45:07we treat patients with STEMI
  • 45:09and multivessel disease. We do
  • 45:10complete revascularization
  • 45:12of angiographically
  • 45:13guided seventy percent or more
  • 45:15stenosis.
  • 45:16So can we do better?
  • 45:18And I'm telling you, I
  • 45:19think we can do better.
  • 45:20And why is that? Well,
  • 45:21they did an OCT substudy
  • 45:23where they actually used OCT
  • 45:25of all three vessels,
  • 45:27within this study, and they
  • 45:28actually found that two thirds
  • 45:30of the patients
  • 45:31had thin cap fibroatheromas.
  • 45:34And, the lesions that were
  • 45:36obstructive, those seventy percent untreated
  • 45:38lesions, that was about thirty
  • 45:40five percent per lesion,
  • 45:42was a thin cap fibroatheroma.
  • 45:44But all of the non
  • 45:45obstructive lesions,
  • 45:46that... They were often thin
  • 45:48cat fibroatheromas
  • 45:49as well. So, overall, fifty
  • 45:51six percent
  • 45:52of these untreated lesions that
  • 45:55got randomized,
  • 45:56the ones that were nonobstructive,
  • 45:58more of those were thin
  • 45:59cat fibroatheromas
  • 46:01than the ones they treated.
  • 46:02And if you looked at
  • 46:03the characteristics
  • 46:04of the lesions that got
  • 46:05treated and didn't get treated,
  • 46:06they look exactly the same
  • 46:07by intravascular imaging.
  • 46:09So I think, actually, they
  • 46:10probably could have more than
  • 46:11doubled the treatment effect size
  • 46:13if they had treated all
  • 46:14the other lesions, but they,
  • 46:16of course, were seduced by
  • 46:17the angiogram. They said that
  • 46:18the seventy percent stenosis, those
  • 46:19are the ones we should
  • 46:20pay attention to. But, actually,
  • 46:22the reason the trial
  • 46:23succeeded
  • 46:24was, in my opinion, is
  • 46:26that they treated the thin
  • 46:27cap fibroatheromas
  • 46:29within those seventy percent stenosis.
  • 46:32So
  • 46:33no one else short of
  • 46:35Eugene Braunwald,
  • 46:37two decades ago
  • 46:39thought that we need to
  • 46:40think out of the box.
  • 46:41Okay? We need to do
  • 46:43vulnerable plaque and vulnerable patient
  • 46:45screening and treatment.
  • 46:46And he said that, basically,
  • 46:47we should start with the
  • 46:48framing and risk score to
  • 46:49risk stratify patients.
  • 46:51And the patients that have
  • 46:52somewhat increased risk, of course,
  • 46:54should have risk factor modification.
  • 46:56But then those that were
  • 46:57the high... Highest risk should
  • 46:59have some sort of noninvasive
  • 47:00assessment for vulnerable plaques.
  • 47:03And that if you detect
  • 47:04vulnerable plaques by noninvasive
  • 47:06assessment,
  • 47:06that you should then have
  • 47:08an invasive test for vulnerable
  • 47:09plaques. And then if you
  • 47:11find vulnerable plaques, you should
  • 47:13do some sort of new
  • 47:14treatment. He didn't know what
  • 47:15the new treatment was back
  • 47:16then.
  • 47:17So I would say that
  • 47:18we have these. We we
  • 47:20we can further risk stratify
  • 47:21patients beyond our
  • 47:23our classic risk factors
  • 47:25by looking for underlying inflammation.
  • 47:27Simple tests such as the
  • 47:29HSCRP,
  • 47:30which again reflects...
  • 47:32Is very related to the
  • 47:33progression of atherosclerosis
  • 47:34and the destabilization
  • 47:36of plaques.
  • 47:37And then that can lead
  • 47:38us to do noninvasive
  • 47:39testing,
  • 47:40such as CTA. And CTA,
  • 47:42especially with photon counting CTA,
  • 47:44is really emerging as the
  • 47:45noninvasive
  • 47:46test for this type of
  • 47:47screening.
  • 47:48Then we can go to
  • 47:49the lab, and, yes, we
  • 47:51have NIRS IVUS, and we
  • 47:52have OCT. We can now
  • 47:53confirm,
  • 47:55you know, beyond certainty what
  • 47:56vulnerable plaques are, and we
  • 47:58actually do have new treatments
  • 48:00per... We have pharmacologic intensification,
  • 48:02and we have stents and
  • 48:04scaffolds.
  • 48:06So
  • 48:07we have four randomized trials
  • 48:09looking at pharmacologic therapy, either
  • 48:11high dose statins or PCSK
  • 48:13nine inhibitors
  • 48:14in patients specifically with vulnerable
  • 48:16plaques. And these were mechanistic
  • 48:18studies. They were imaging studies
  • 48:20where they did find specifically
  • 48:22vulnerable plaques,
  • 48:23and then they randomized patients
  • 48:25to either placebo or hydostat
  • 48:26or PCSK nine inhibitors. And
  • 48:28all four trials were positive.
  • 48:30They showed that what you
  • 48:31would do is you would
  • 48:33delipidate the plaque with intensive,
  • 48:35LDL lowering therapy.
  • 48:36You would thicken the fibrous
  • 48:38cap, and you would slightly
  • 48:39decrease plaque burden, but only
  • 48:41one to two percent. The
  • 48:43main effects are not on
  • 48:44plaque burden. It's on the,
  • 48:46compositional
  • 48:47structure of the plaque.
  • 48:49So how big an effect
  • 48:50does this have?
  • 48:51Well, if you're not targeting
  • 48:53patients with vulnerable plaque and
  • 48:55you wanna treat everybody, which
  • 48:56is what big pharma always
  • 48:57wants to do, you do
  • 48:59have a positive effect, but
  • 49:00it's a minimal effect. So
  • 49:02if you look at the
  • 49:03Fourier and the ODSI outcomes,
  • 49:05outcome trials in twenty to
  • 49:07thirty thousand randomized patients, these
  • 49:09are the PCSK nine inhibitor
  • 49:11trials, they're both positive.
  • 49:13But look at one, how
  • 49:14much they're positive.
  • 49:15They reduce major adverse cardiac
  • 49:17events by about two percent
  • 49:20in a four year period.
  • 49:21So it's about point five
  • 49:23percent per year, and you
  • 49:24can see there's still a
  • 49:25high residual risk at the
  • 49:27end of the day. So
  • 49:28they are having some effect,
  • 49:30but you're treating a lot
  • 49:31of patients who probably don't
  • 49:33need to be treated, and
  • 49:34you are having some effect
  • 49:35on the ones that do
  • 49:36need to be treated, but
  • 49:37it's a small overall global
  • 49:40effect.
  • 49:42So we and others had
  • 49:43come up with the idea
  • 49:44that perhaps
  • 49:45we're treating the wrong lesions
  • 49:46with stents and with bypass
  • 49:48surgery, but this is probably
  • 49:49most relevant to stents. And
  • 49:50if we could identify vulnerable
  • 49:52plaques, like you've got here
  • 49:54an LAD. This was from
  • 49:56two. Here's a ten percent
  • 49:57osteoLED
  • 49:58stenosis.
  • 49:59Nobody in their right mind
  • 50:00today would think about treating
  • 50:01this. But when you image
  • 50:03this with IVUS and, near
  • 50:05infrared spectroscopy,
  • 50:06you see a seventy five
  • 50:07percent bulky plaque with a
  • 50:10very high lipid content, a
  • 50:12sixty percent lipid.
  • 50:13This is a, quote, widow
  • 50:14maker lesion. And this is
  • 50:16just as high risk a
  • 50:17plaque as if it looked
  • 50:18like this, but it was
  • 50:19an eighty percent stenosis.
  • 50:21So you... What you could
  • 50:23do is you could either
  • 50:24leave that alone and take
  • 50:25a chance that it might
  • 50:26rupture in thrombose,
  • 50:28or perhaps you'd put a
  • 50:29stent on it. And a
  • 50:30stent in a scaffold
  • 50:32always invokes an obligate amount
  • 50:34of healing response, which is
  • 50:35what's called neointimal hyperplasia or
  • 50:38scar tissue. And our concept
  • 50:39and others' concepts were that
  • 50:41the scar tissue would thicken
  • 50:43the cap. So you now
  • 50:44make a thick fibrous cap.
  • 50:46And, also, by dilating, you
  • 50:47also help dilipidate the plaque.
  • 50:50So this was proven pathologically
  • 50:52by Pedro Marino and others.
  • 50:54They, you know, fed,
  • 50:56rabbits, hypercholesterolemic
  • 50:58diet, and they could create,
  • 50:59these foam cell laden lesions
  • 51:01that look like thin cap
  • 51:02fibroatheromas.
  • 51:04And they would stent them,
  • 51:05and they would then,
  • 51:06find out that this is
  • 51:07what it would look like.
  • 51:08And you could see here
  • 51:09basically the, oblong stent strut.
  • 51:12And below in blue, you
  • 51:13could see the old fibrous
  • 51:15cap, and then you could
  • 51:16see the neointema on top,
  • 51:18which is the new fibrous
  • 51:19cap. So you took what
  • 51:20was a sixty micron,
  • 51:22fibrous cap, and now you
  • 51:23turn it into a two
  • 51:24hundred and fifty micron fibrous
  • 51:25cap.
  • 51:27So we ran the first
  • 51:28pilot study called Prospect Absorb
  • 51:30to see if this would
  • 51:31be safe. Could it could...
  • 51:32Could you even do this,
  • 51:33and would it mechanistically work?
  • 51:35And what we did was
  • 51:36we randomized a hundred and
  • 51:37eighty two patients,
  • 51:39that had a large plaque
  • 51:41burden and non flow limiting
  • 51:42lesions to either get a
  • 51:44bioresorbable
  • 51:45scaffold called the absorb scaffold
  • 51:47versus medical therapy alone, and
  • 51:49we followed the patients for
  • 51:51four years.
  • 51:52And we brought them all
  • 51:53back to reimage them at
  • 51:55twenty five months to see
  • 51:56if, mechanistically,
  • 51:58it would happen what we
  • 51:59thought would happen.
  • 52:00And sure enough, we made
  • 52:02the lumen much larger.
  • 52:03You could see the treated
  • 52:05group went from three point
  • 52:06two to six point nine
  • 52:07millimeters squared, whereas the untreated
  • 52:09group stayed the same, or
  • 52:11got slightly smaller.
  • 52:12We created a NeoCap that
  • 52:14was two hundred and ten
  • 52:15microns thick, and we delipidated
  • 52:17the plaque. We went from
  • 52:18thirty three percent lipid down
  • 52:20to about six percent lipid
  • 52:21at twenty five months.
  • 52:23Now this trial at a
  • 52:24hundred and eighty two patients
  • 52:25was not powered for clinical
  • 52:26events, but, nonetheless,
  • 52:28if you look at what
  • 52:29happened with the lesions that
  • 52:30got treated,
  • 52:31there was about over four
  • 52:33years. The ones that were
  • 52:34randomized to use medical therapy
  • 52:35had an eleven percent lesion
  • 52:37specific event rate versus four
  • 52:39percent in the ones that
  • 52:40got a scaffold.
  • 52:42So pictures are always worth
  • 52:43a thousand words.
  • 52:45So here was a patient
  • 52:46that had two lesions.
  • 52:48So here you can see
  • 52:50a circumflex marginal lesion in
  • 52:52the first, angiogram,
  • 52:53and in the second angiogram,
  • 52:55you could see a mid
  • 52:55right coronary lesion. And both
  • 52:57of these had... Were negative
  • 52:58by FFR or point nine
  • 53:00zero, so no indication to
  • 53:01treat today.
  • 53:02They were both
  • 53:04very bulky lipidic plaques.
  • 53:06So when there were two
  • 53:07plaques, we would tell the
  • 53:08operator, randomize the lesion that
  • 53:11looked like it supplied the
  • 53:12most amount of myocardium.
  • 53:13So in this case, they
  • 53:14randomized the right coronary lesion,
  • 53:16and this patient got randomized
  • 53:18to, a biorasorbital
  • 53:20scaffold.
  • 53:21And so here it was
  • 53:22before, and here it was
  • 53:23after the scaffold. And you
  • 53:25could see the lumen is
  • 53:26larger. We dilipidated the plaque.
  • 53:28You see the yellow rim
  • 53:29that shows you where the
  • 53:30lipid is, and there was
  • 53:31lipid at baseline. There's no
  • 53:33lipid afterwards.
  • 53:35So the patient did really
  • 53:36well for about nine months
  • 53:38and then came back with
  • 53:40progressive angina, and so the
  • 53:41patient got recapped at nine
  • 53:43months. And the right coronary
  • 53:45looked beautiful.
  • 53:46Okay? But the circumflex... And
  • 53:47this is the one that
  • 53:48was not treated. Here's what
  • 53:50happened. This was again a
  • 53:51vulnerable plaque, and the circumflex
  • 53:54occluded
  • 53:55in that nine month period.
  • 53:57So the operator said, well,
  • 53:58this is a moderate sized
  • 54:00vessel. I don't think I'd
  • 54:01have a very good chance
  • 54:02of opening it up. Let
  • 54:03me just leave this alone,
  • 54:04and we'll treat the patient
  • 54:05with more anti anginal drugs
  • 54:06because it's now very, very
  • 54:07stable.
  • 54:08And that's what it did.
  • 54:09The patient ended up with
  • 54:10mild angina, but was stable.
  • 54:12And then the patient came
  • 54:13back at twenty five months.
  • 54:15The circumflex looked the same,
  • 54:16and here's what the right
  • 54:17corner looked like. So you
  • 54:19got baseline, immediate after, in
  • 54:20the middle, and then at
  • 54:22twenty five months. And now
  • 54:23you can see we've, quote,
  • 54:24stabilized
  • 54:25this vulnerable plaque.
  • 54:27But what we clearly needed
  • 54:28was an outcomes trial,
  • 54:30and, we couldn't get one
  • 54:31funded in the United States.
  • 54:33So, fortunately, in South Korea,
  • 54:36they had funding to be
  • 54:37able to do this. So
  • 54:38I worked with a leading
  • 54:40South Korean group, SJ Park,
  • 54:41who's published a lot of
  • 54:42papers in the journal,
  • 54:44and we designed the PREVENT
  • 54:45trial. And this was sixteen
  • 54:47hundred patients
  • 54:48with a flow,
  • 54:50a negative flow... A non
  • 54:51flow limiting vulnerable plaque,
  • 54:54mostly chronic coronary syndromes that
  • 54:56had no other reason to
  • 54:57treat except they had a
  • 54:58vulnerable plaque. And we used
  • 55:00a variety of different imaging
  • 55:01techniques that could be used,
  • 55:02and they got randomized one
  • 55:04to one to either, bioresorbable
  • 55:06scaffold or metallic drug eluting
  • 55:08stent versus medical therapy alone.
  • 55:10And this was a powered
  • 55:11randomized trial to reduce target
  • 55:13vessel failure at two years.
  • 55:15And as we published in
  • 55:16The Lancet,
  • 55:18yes, target vessel failure, the
  • 55:20the vessel that had that
  • 55:21vulnerable plaque, three point four
  • 55:23percent of them within two
  • 55:24years had major adverse events
  • 55:26compared to point four percent
  • 55:28that had preventive
  • 55:30PCI treatment. So almost a
  • 55:32ninety percent reduction.
  • 55:33Almost almost too good to
  • 55:35be true.
  • 55:36When you look at the
  • 55:37kind of events that were
  • 55:38prevented,
  • 55:38a lot of it was
  • 55:39unstable angina and unplanned repeat
  • 55:41revascularization,
  • 55:42but there was a reduction
  • 55:43in death or target vessel
  • 55:45MI as well. So everything
  • 55:46went in the right direction.
  • 55:49The patients were followed up
  • 55:51for seven years total, and
  • 55:53that initial benefit,
  • 55:55lasted throughout the seven year
  • 55:56follow-up.
  • 55:59And the trial could have
  • 56:00been even more positive, and
  • 56:01this is a manuscript which
  • 56:02is in press, which will
  • 56:03be published in about one
  • 56:04week because
  • 56:06they relied very heavily on
  • 56:08grayscale IVUS in that trial.
  • 56:10But grayscale IVUS mainly shows
  • 56:12you just the plaque. It
  • 56:13doesn't tell you the type
  • 56:14of plaque.
  • 56:15And there were a number
  • 56:17of patients that had grayscale
  • 56:19IVUS with near spectroscopy.
  • 56:21And when we looked at
  • 56:22the ones that had a
  • 56:23lot of plaque
  • 56:24and a lot of lipid,
  • 56:25that's the ones on the
  • 56:26left, now you see a
  • 56:27very high event rate and
  • 56:29a marked effect of preventive
  • 56:31PCI.
  • 56:32In contrast, if you look
  • 56:33at the graph on the
  • 56:34right, those were the bulky
  • 56:36plaques that had very little
  • 56:37lipid in them. And those
  • 56:39plaques really do great even
  • 56:40though they have very little
  • 56:41lipid. They're they're not obstructive.
  • 56:43A lot of atherosclerosis,
  • 56:45but these are not vulnerable
  • 56:46plaques. Leave them alone. You
  • 56:48don't benefit them, and very
  • 56:50little happens to them. So,
  • 56:51again, if we were more
  • 56:52restrictive at which lesions were
  • 56:54enrolled, this could have been
  • 56:55much more positive.
  • 56:57So
  • 56:59there are a lot of
  • 57:00other trials that are going
  • 57:01on to look at preventative
  • 57:03PCI in vulnerable plaque. The
  • 57:05first two, as I showed
  • 57:05you here, Prospect, Absorb, and
  • 57:07Prevent, have been done and
  • 57:08were both positive for their
  • 57:09endpoints.
  • 57:11There's, three others, vulnerable, combined,
  • 57:13intervene, and interclima, which have
  • 57:14completed enrollment and will report
  • 57:16out within the next one
  • 57:17to two and a half
  • 57:18years depending on follow-up.
  • 57:20And we're doing a trial
  • 57:22in China called FABR five
  • 57:23AMI, which is the largest
  • 57:25of all of these, at
  • 57:26three thousand patients,
  • 57:28looking at a novel vulnerable
  • 57:29plaque detection methodology.
  • 57:31So there's gonna be a
  • 57:32lot more data to come.
  • 57:34There's also one trial, which
  • 57:35has started recently in China,
  • 57:37that I helped them design
  • 57:39called the RESTORE trial,
  • 57:40and this is actually using
  • 57:41a drug coated balloon.
  • 57:43So everyone likes this concept
  • 57:44of leaving nothing behind if
  • 57:46you're gonna treat these nonflow
  • 57:47limiting plaques just to change
  • 57:49the morphology of the,
  • 57:51of the... Of this lesion
  • 57:52without,
  • 57:54again, putting in a permanent
  • 57:55implant. So here, we're trying
  • 57:56it with a drug coated
  • 57:57balloon in a sixteen hundred
  • 57:59patient randomized... Eighteen hundred and
  • 58:01sixty patient randomized outcomes trial.
  • 58:04So this is my last
  • 58:05slide, and now I'll see
  • 58:07if you've been paying attention.
  • 58:09So should we look for
  • 58:10and should we revascularize
  • 58:11vulnerable plaques? So this is
  • 58:13a real patient. This was
  • 58:14a sixty five year old
  • 58:15man with exertional dyspnea, was
  • 58:17a prior smoker,
  • 58:18had hypertension, hypercholesterolemia.
  • 58:20His LDL was sixty eight
  • 58:21milligrams for desalita on atorvastatin.
  • 58:24He had a stress echo,
  • 58:26and he had a millimeter
  • 58:27of exertional ST segment depression,
  • 58:29but normal resting and normal
  • 58:31stress LVEF.
  • 58:33Okay. So let me ask
  • 58:34you the first question. How
  • 58:35many people here would do
  • 58:37an angiogram
  • 58:38versus treat conservatively?
  • 58:40So who would do an
  • 58:41angiogram
  • 58:43with this? I'll let you
  • 58:44read it for a second.
  • 58:47Lot of risk factors,
  • 58:49exertional dyspnea, no angina, but
  • 58:51exertional dyspnea,
  • 58:52and a little bit of
  • 58:53an EKG response on stress
  • 58:55echo, but normal stress and
  • 58:57rest LV function.
  • 59:00Angiogram, anybody?
  • 59:02Angiogram.
  • 59:04Okay. Interventional cardiologist said, yeah.
  • 59:06Yeah. Yeah. Yeah. Alexander said
  • 59:08a CT angiogram.
  • 59:09Well, it turns out that
  • 59:10this patient was the CEO
  • 59:13of a Fortune five hundred
  • 59:14company.
  • 59:15Okay? So, of course, this
  • 59:16patient got capped.
  • 59:17Okay? That's okay.
  • 59:20And here's what the cat
  • 59:21showed.
  • 59:22And this patient had, again,
  • 59:24whistle clean coronary arteries except
  • 59:26for these two lesions
  • 59:28in the proximal and the
  • 59:29mid LAD.
  • 59:31Okay?
  • 59:32So they're both maybe twenty
  • 59:33percent, maybe thirty percent lesions.
  • 59:35Okay?
  • 59:38So what do you wanna
  • 59:40do now? Do you wanna...
  • 59:41Do you want to assess
  • 59:42those? Do you wanna do
  • 59:43a physiologic test to see
  • 59:45if they're flow limiting?
  • 59:47Maybe that's... You know, that
  • 59:48would tell you... That would
  • 59:49correlate with his exertional dyspnea.
  • 59:51Right? So that's the first
  • 59:52thing the doc said to
  • 59:53do, and so he did
  • 59:54a fractional flow reserve, and
  • 59:56it was point eight eight.
  • 59:58So those two lesions, even
  • 59:59in in concert, are not
  • 01:00:01flow limiting. So his exertional
  • 01:00:03dyspnea is probably not related
  • 01:00:05to any of this.
  • 01:00:07Okay? So now do you
  • 01:00:08wanna stop?
  • 01:00:09Well, again, this was a
  • 01:00:11CEO of a Fortune five
  • 01:00:13hundred company. So this operator
  • 01:00:15said, who who is at
  • 01:00:16a very famous institution, by
  • 01:00:18the way, said, I'm gonna
  • 01:00:19go ahead and I'm gonna
  • 01:00:20do,
  • 01:00:21a nearest IVUS.
  • 01:00:23And here are those two
  • 01:00:24lesions.
  • 01:00:25Okay? So both of those
  • 01:00:27lesions are what we would
  • 01:00:28call vulnerable plaques. The first
  • 01:00:30lesion's got a plaque burden
  • 01:00:31of seventy one percent, and
  • 01:00:33it's fifty seven percent lipid.
  • 01:00:35Thirty two percent lipid is
  • 01:00:36about our cutoff of where
  • 01:00:37we get really nervous.
  • 01:00:40So sixty percent lipid. The
  • 01:00:41second lesion is seventy four
  • 01:00:43percent plaque burden and thirty
  • 01:00:45six percent lipid. So both
  • 01:00:47of those are vulnerable plaques.
  • 01:00:49Okay? So now what do
  • 01:00:51you do?
  • 01:00:52Should PCI
  • 01:00:53Do you tell the patient
  • 01:00:54about this? We know the
  • 01:00:56patient's at higher risk.
  • 01:00:57Okay? Should you put the
  • 01:00:59patient on a PCSK nine
  • 01:01:00inhibitor, get his LDL down
  • 01:01:01to twenty? Should that be?
  • 01:01:03Okay. All you do. What
  • 01:01:05if you talk to the
  • 01:01:05patient and he's one of
  • 01:01:07these, you know, aggressive guys,
  • 01:01:08and he goes, doc, I
  • 01:01:09want you to do everything.
  • 01:01:10I realize it's not
  • 01:01:12indicated by any guidelines anywhere.
  • 01:01:15Well, I think, yes, you'd
  • 01:01:16probably today put the patient
  • 01:01:17on a PCSK nine inhibitor.
  • 01:01:19I don't think you'd do
  • 01:01:20PCI today, but I'm hoping
  • 01:01:22potentially tomorrow after we get
  • 01:01:24more data from these randomized
  • 01:01:25trials. Thanks very much.
  • 01:01:44Maybe I'll start and get,
  • 01:01:45and Alexander's can go next.
  • 01:01:47So are there any
  • 01:01:49elements of people's presentation? And
  • 01:01:52I'm... And you know I'm
  • 01:01:52gonna ask you about Yeah.
  • 01:01:54LV dysfunction
  • 01:01:55Yeah. Or heart failure symptoms
  • 01:01:57that would
  • 01:01:58take taking this patient based
  • 01:01:59on what she taught us
  • 01:02:00about bromo pry that would
  • 01:02:02push you
  • 01:02:03to a different answer to
  • 01:02:05to... For today? Yeah. Well,
  • 01:02:07you know, the the main
  • 01:02:08two clinical...
  • 01:02:09Sure.
  • 01:02:10Well, the main two clinical
  • 01:02:11risk factors
  • 01:02:13for having thin cat fibroatheromas
  • 01:02:16are one, having had either
  • 01:02:18an acute or prior acute
  • 01:02:19coronary syndromes. So patients who
  • 01:02:21have had a prior myocardial
  • 01:02:22infarction or unstable angina, again,
  • 01:02:24which are not... They're not
  • 01:02:26always called by thin cat
  • 01:02:27fibroarthromas, by the way. That's
  • 01:02:28probably seventy five percent of
  • 01:02:29the time I didn't get
  • 01:02:30in... Don't have time to
  • 01:02:31get into erosion plaques and
  • 01:02:32calcific nodules and things. But
  • 01:02:35if you had one thin
  • 01:02:36cat fibroarthroma
  • 01:02:37presentation,
  • 01:02:38you're more likely to have
  • 01:02:39others in the coronary tree.
  • 01:02:41So that's number one. And
  • 01:02:42then the second big one
  • 01:02:43is diabetes.
  • 01:02:44So diabetic patients are more
  • 01:02:46likely to have thin cap
  • 01:02:47fibroathero.
  • 01:02:48So those two situations
  • 01:02:49raise your suspicion,
  • 01:02:51in the individual patient.
  • 01:02:53LV dysfunction, of course, if
  • 01:02:54you have LV dysfunction because
  • 01:02:55you had a priori,
  • 01:02:57that not only makes it
  • 01:02:58more likely that you do
  • 01:02:59have latent thin cat fibroatheromas,
  • 01:03:02but it also is more
  • 01:03:03likely that the next rupture,
  • 01:03:04of course, is gonna be
  • 01:03:05fatal.
  • 01:03:08So my question is even
  • 01:03:09with this patient, many many
  • 01:03:11of us would not send
  • 01:03:13the patient to the cath
  • 01:03:14lab. Right. Right? So you
  • 01:03:16have symptoms. You're... You know,
  • 01:03:17they're
  • 01:03:18equivocal.
  • 01:03:20So
  • 01:03:21do you have any data
  • 01:03:22on the role of CT
  • 01:03:24angiography
  • 01:03:25Yeah. And plaque characterization
  • 01:03:27and outcomes from CTA? Yeah.
  • 01:03:30So there is... And and
  • 01:03:31and Jagged Arula, I think,
  • 01:03:32has generated a lot of
  • 01:03:33that work, and, there have
  • 01:03:35been subsequent studies.
  • 01:03:36They haven't done the types
  • 01:03:38of prospective validation studies on
  • 01:03:40a lesion specific level, but
  • 01:03:42they have shown that that
  • 01:03:44if you have low Hounsfeld
  • 01:03:46unit plaques with positive remodeling,
  • 01:03:48Okay? That... That's the classic
  • 01:03:50two feature high risk plaques
  • 01:03:51by CTA.
  • 01:03:52The third one being the
  • 01:03:53napkin ring sign is the
  • 01:03:54most common,
  • 01:03:56third predictor.
  • 01:03:57That that does identify patients
  • 01:03:59that are at future risk.
  • 01:04:00Probably at the same lesions,
  • 01:04:02but they just haven't done
  • 01:04:03those studies.
  • 01:04:04So... And especially, again, with
  • 01:04:05the newer photon counting CT
  • 01:04:07where, you know, the resolution's
  • 01:04:08down to about two hundred
  • 01:04:10microns, I think, is fair
  • 01:04:11to say.
  • 01:04:12You know, and the delineation
  • 01:04:14you can get, you still
  • 01:04:14can't see the thin fibrous
  • 01:04:16cap, but it's getting really
  • 01:04:17much better delineation for what
  • 01:04:19is lipid versus calcium
  • 01:04:21versus fibrotic plaque. And so,
  • 01:04:23yeah, I think it is
  • 01:04:24it is the screening test.
  • 01:04:28So that was phenomenal
  • 01:04:30talking because all of this
  • 01:04:32came from you. We all
  • 01:04:33believe every single word. No.
  • 01:04:35No. Yeah. So Don't don't
  • 01:04:37do that. Trying... I was
  • 01:04:38trying to figure out what
  • 01:04:39you were wanting us to
  • 01:04:40say and answer the questions
  • 01:04:42that way.
  • 01:04:43But, you know, what you
  • 01:04:45described is sort of
  • 01:04:47good news because more information
  • 01:04:48is always good news and
  • 01:04:50bad news because if you
  • 01:04:51do
  • 01:04:52coronary angiograms
  • 01:04:53or if you did
  • 01:04:55OCT or
  • 01:04:57spectroscopy,
  • 01:04:59studies on a thousand people
  • 01:05:01who you took off the
  • 01:05:02street, you would probably find
  • 01:05:04thin cap fibroatheomas
  • 01:05:07in many, many of them.
  • 01:05:08Right. So, you know, it
  • 01:05:09almost raises the question, should
  • 01:05:11this be like screening colonoscopies
  • 01:05:13that everyone needs to get
  • 01:05:15one of these Yeah. And
  • 01:05:16be followed along serially because
  • 01:05:18of that. And I I
  • 01:05:19think that's
  • 01:05:21maybe a little bit
  • 01:05:22of a facetious question, but
  • 01:05:24it it makes all of
  • 01:05:25us probably nervous to to
  • 01:05:27hear this lecture and to
  • 01:05:28and to think about that.
  • 01:05:30One of the things about
  • 01:05:31medical therapy that I think
  • 01:05:32we're... And,
  • 01:05:33you know, you didn't talk
  • 01:05:35about too much, but, you
  • 01:05:36know, it's the inflammation part
  • 01:05:38of this. Yeah. I can't
  • 01:05:38help but but bring that
  • 01:05:40up. I mean, I've been
  • 01:05:40around long enough that
  • 01:05:43the cholesterol people and the
  • 01:05:44inflammation vascular biologists were arguing
  • 01:05:47about what causes Yeah. Afterone.
  • 01:05:49Clearly, it's both. Right. Right?
  • 01:05:51And so PCSK nine inhibitors
  • 01:05:53don't have those pleiotropic
  • 01:05:55effects of Right. Anti inflammation
  • 01:05:57that statins do. But do
  • 01:05:58you wanna comment
  • 01:06:00on any any Yeah. On
  • 01:06:01sort of newer anti inflammatory
  • 01:06:03therapies that might be
  • 01:06:05Yeah. Well, I... And I'm
  • 01:06:07a I'm a big believer
  • 01:06:08in the inflammatory
  • 01:06:09hypothesis as well.
  • 01:06:11And, I mean, clearly, it
  • 01:06:13can work. I mean, canakinumab
  • 01:06:15worked, right, in the CANTOS
  • 01:06:16trial.
  • 01:06:18It it also led to
  • 01:06:19fatal infections.
  • 01:06:20But, you know, but inhibiting
  • 01:06:22I l one, you know,
  • 01:06:23which is very high upstream
  • 01:06:24in the pathway worked. I
  • 01:06:26think we were all really,
  • 01:06:28disappointed
  • 01:06:29when, you know, the last
  • 01:06:31two negative trials have been
  • 01:06:32released, and the IL six
  • 01:06:33inhibitor did not work. We
  • 01:06:35have... We'll see those results,
  • 01:06:36I think, at the this
  • 01:06:37year. But, we have to
  • 01:06:39understand more, and we're still
  • 01:06:40searching for where exactly in
  • 01:06:42the inflammatory
  • 01:06:43cascade do we interrupt that
  • 01:06:44it is the right place.
  • 01:06:46This all works through the
  • 01:06:47NLRP three inflammasome,
  • 01:06:49and so the question is
  • 01:06:50how do we inhibit that
  • 01:06:51from forming? And so I
  • 01:06:52do think they're gonna get
  • 01:06:54better and better at at
  • 01:06:55finding the right drugs,
  • 01:06:56you know,
  • 01:06:57to interrupt inflammation.
  • 01:06:59But I do think that
  • 01:07:00what the,
  • 01:07:01pharma community is doing wrong
  • 01:07:03is they they wanna treat
  • 01:07:05tens of millions of people.
  • 01:07:07And so we're treating a
  • 01:07:08lot of people that don't
  • 01:07:09need to be treated. And
  • 01:07:11so they're always gonna get
  • 01:07:12these very small effect sizes
  • 01:07:14because nine... If ninety percent
  • 01:07:15of people don't need to
  • 01:07:16be treated, they're just gonna
  • 01:07:17dilute out all the benefit
  • 01:07:18of the other patients who
  • 01:07:19are having a marked benefit.
  • 01:07:21That's why all the device
  • 01:07:22trials always show these huge
  • 01:07:24reductions
  • 01:07:25in hazard ratios because they're
  • 01:07:26only treating the very specific
  • 01:07:28patients that need to be
  • 01:07:29treated. It's not that devices
  • 01:07:31are better than drugs. It's
  • 01:07:32that we're treating the right
  • 01:07:32patients.
  • 01:07:37So, Greg, thank you so
  • 01:07:38much for this incredible talk.
  • 01:07:39And, I would like to
  • 01:07:40touch upon your vision for
  • 01:07:42the future, where you see
  • 01:07:43that we're gonna be stenting
  • 01:07:44those, you know, very mild
  • 01:07:46lesions.
  • 01:07:47And earlier today, we were
  • 01:07:48discussing about most of the
  • 01:07:50procedures are still angio guided.
  • 01:07:52Right? So people don't use
  • 01:07:53intravascular imaging very much. And
  • 01:07:55you get situations like these
  • 01:07:56where you have lesions close
  • 01:07:57to the left main, so
  • 01:07:58there will be angio guided
  • 01:07:59procedures, you know, in different
  • 01:08:02situations where stents are gonna
  • 01:08:03be suboptimal implanted.
  • 01:08:05Do you, are you concerned
  • 01:08:06that we're gonna be trading
  • 01:08:07the natural history risk
  • 01:08:10with these more stent related,
  • 01:08:12events
  • 01:08:12somehow? Well, what you've seen,
  • 01:08:14at least so far, the
  • 01:08:15two randomized trials that have
  • 01:08:17been done, and there have
  • 01:08:18been... These are very soft
  • 01:08:19lesions. They're very easy to
  • 01:08:21treat with stents. And while
  • 01:08:23the complications aren't gonna be
  • 01:08:24zero and you're gonna occasionally
  • 01:08:26get a restenosis,
  • 01:08:28so far, they actually been
  • 01:08:29in no stent thrombosis in
  • 01:08:30either of the two trials.
  • 01:08:31And you saw... I mean,
  • 01:08:33so far, the overall MACE
  • 01:08:34risk, which includes all those
  • 01:08:36stent related events, seems like
  • 01:08:38it might be substantially less
  • 01:08:39than the natural history risk.
  • 01:08:41But that's the trade off,
  • 01:08:42to find the right lesions
  • 01:08:43that have a high enough
  • 01:08:44risk so that you can
  • 01:08:46absorb some of the risk.
  • 01:08:47Every procedure's got complications, so
  • 01:08:48you can absorb some of
  • 01:08:49those risks.
  • 01:08:53Thanks so much, Erica Spatz.
  • 01:08:54I'm a preventive cardiologist. So
  • 01:08:56Good. Coming at it from
  • 01:08:58the other way. So when,
  • 01:09:00we... You know,
  • 01:09:02a lot of us in
  • 01:09:03the community looking at the
  • 01:09:04PREVENT trial saw that a
  • 01:09:06lot of the events were
  • 01:09:07driven by nonacute events of
  • 01:09:09revascularization
  • 01:09:11and maybe out of jealousy
  • 01:09:12that you guys did the
  • 01:09:13outcomes trial first before we
  • 01:09:14did the medical therapy one.
  • 01:09:16But,
  • 01:09:17what you were saying, you
  • 01:09:19know, in terms of
  • 01:09:20this vulnerable
  • 01:09:22plaque is true for, you
  • 01:09:23know, a vulnerable coronary tree.
  • 01:09:25So it could be this,
  • 01:09:26like, whack a mole situation
  • 01:09:28where you identify one hot
  • 01:09:30lesion, and then you got
  • 01:09:31another one and another one.
  • 01:09:33And,
  • 01:09:34you know, what we've been
  • 01:09:36thinking about is more of
  • 01:09:37this residual risk.
  • 01:09:39So what can we
  • 01:09:41continually,
  • 01:09:43modify
  • 01:09:44with medications?
  • 01:09:46What's left to be modified.
  • 01:09:48And then, you know, so
  • 01:09:49maybe there is sort of
  • 01:09:50a
  • 01:09:51a a strategy that, you
  • 01:09:53know, puts people down a
  • 01:09:54path where
  • 01:09:56potentially PCI is that last
  • 01:09:59resort when you still have
  • 01:10:00these residual plaques that are
  • 01:10:02high burden or in these,
  • 01:10:03like, acute coronary situations where
  • 01:10:05you're already in the... In
  • 01:10:06there and you're looking at,
  • 01:10:08you know, the the rest
  • 01:10:09of the tree. So what
  • 01:10:10are your thoughts on, you
  • 01:10:11know, more of a strategic
  • 01:10:13approach for more personalized care?
  • 01:10:15So there's, like, three or
  • 01:10:16four different different questions in
  • 01:10:18there, so it's so it's
  • 01:10:19great.
  • 01:10:21So first of all, the
  • 01:10:22one thing that we don't
  • 01:10:23know about drug therapy, I
  • 01:10:25showed you some of the
  • 01:10:25mechanistic studies that were done,
  • 01:10:27the four randomized trials.
  • 01:10:29Those were also... Always done
  • 01:10:31on mild to moderate plaques.
  • 01:10:33Okay? We don't know if
  • 01:10:34once you have a well
  • 01:10:36formed vulnerable plaque that's more
  • 01:10:37than seventy percent plaque burden
  • 01:10:39with a thin fibrous cap
  • 01:10:40and a lot of lipid,
  • 01:10:41we don't know if the
  • 01:10:43drugs will act fast enough
  • 01:10:44to be able to stabilize
  • 01:10:46those. So that's one question.
  • 01:10:48The second thing is what
  • 01:10:49you say is absolutely very
  • 01:10:50true about whack a mole
  • 01:10:52to some extent.
  • 01:10:54But we've seen that for
  • 01:10:56about three to four years,
  • 01:10:58it takes several
  • 01:10:59years. These lesions do change
  • 01:11:01morphology, but it takes several
  • 01:11:03years for that to happen.
  • 01:11:04So if you take care
  • 01:11:05of, quote, the tiktvas
  • 01:11:07at time zero, as you
  • 01:11:09see, you're probably pretty good
  • 01:11:11for about three to four
  • 01:11:12years. And then if you
  • 01:11:13can then give your preventative
  • 01:11:15background therapy so you don't
  • 01:11:16get new ones developed,
  • 01:11:18you know, then you're probably
  • 01:11:19in good shape. So I
  • 01:11:20think these are more complementary
  • 01:11:21approaches rather than, competitive approaches.
  • 01:11:24The third thing, and perhaps
  • 01:11:25most complicated aspect though, is
  • 01:11:27how do you find these
  • 01:11:29things? I mean,
  • 01:11:30you've got, again, you know,
  • 01:11:32as you mentioned, you know,
  • 01:11:33the the walking well that
  • 01:11:34don't know they're walking around
  • 01:11:36with them. But those patients
  • 01:11:37have, the average person, very
  • 01:11:39low levels of inflammation,
  • 01:11:41and their per year risk
  • 01:11:42is probably quite small,
  • 01:11:45patients who are asymptomatic
  • 01:11:46or have non cardiac symptoms.
  • 01:11:48So for those patients, I
  • 01:11:50like the Braunwald algorithm. Let's
  • 01:11:52identify the ones with a
  • 01:11:53lot of risk factors that
  • 01:11:54are more likely to have
  • 01:11:55them, perhaps use CRP or
  • 01:11:57other, test to screen for
  • 01:11:59inflammation,
  • 01:11:59and then go down a
  • 01:12:01more noninvasive and invasive screening
  • 01:12:03category that ultimately applies to
  • 01:12:05five percent or ten percent
  • 01:12:06of the population at most.
  • 01:12:08But if you're in the
  • 01:12:09lab with a patient with
  • 01:12:10an acute coronary syndrome,
  • 01:12:12on average, from from all
  • 01:12:13of our studies, once you
  • 01:12:14present with an MI,
  • 01:12:16you've got another four and
  • 01:12:17a half lesions on average
  • 01:12:19throughout the coronary tree. And
  • 01:12:21one to two of those
  • 01:12:23on average are thin cap
  • 01:12:24fibroatheromas.
  • 01:12:26So maybe then and there,
  • 01:12:27you should be treating them
  • 01:12:28the way we'd complete
  • 01:12:30the trial. We're now treating
  • 01:12:31all the seventy percent stenoses.
  • 01:12:33If we can identify the
  • 01:12:34ones that are... That really
  • 01:12:35need the treatment, it's not
  • 01:12:36the seventy percent stenosis, but
  • 01:12:38you're leaving behind half of
  • 01:12:39the others that need to
  • 01:12:40be treated as well. So
  • 01:12:42I think there's complimentary ways
  • 01:12:43to work all of this
  • 01:12:44into the best management.
  • 01:12:46To ask a question, David.
  • 01:13:00Thank you very much.
  • 01:13:03Right. Thank you. Wonderful talk.
  • 01:13:05I'm wondering the, collagen content
  • 01:13:08decide the cap, sing, or
  • 01:13:10stick. So, typically, the synthetic
  • 01:13:14produce a collagen Yeah. To
  • 01:13:15stabilize. What do you think
  • 01:13:17about all kinds of therapy?
  • 01:13:18Could you stabilize the cap
  • 01:13:20smooth muscle cell under
  • 01:13:21synthetic step
  • 01:13:23or,
  • 01:13:24contractor or, like, a smooth
  • 01:13:25muscle cell toward macrophage, which
  • 01:13:27may degrade the collagen? What
  • 01:13:29are thoughts about, the root
  • 01:13:30issue of this thin thick
  • 01:13:32cap? Yeah. Wait. Wait. Yeah.
  • 01:13:34Absolutely. I mean, there may
  • 01:13:35be newer therapies that can
  • 01:13:37do that, and it's not
  • 01:13:38normal. Even though it's thin,
  • 01:13:40what... It is thin, but
  • 01:13:41it's not only thin. It's
  • 01:13:43also abnormal collagen. So if
  • 01:13:44type one collagen is replaced
  • 01:13:46by type three collagen in
  • 01:13:47addition to all the inflammation
  • 01:13:49going on in the cap.
  • 01:13:50So, yeah, it is possible
  • 01:13:51that there... You know? And
  • 01:13:52and there are targeted therapies
  • 01:13:54that are being worked on
  • 01:13:55for the extracellular matrix to
  • 01:13:57thicken the cap and to
  • 01:13:58stabilize the cap in other
  • 01:13:59ways.
  • 01:14:02Excellent talk. I really enjoyed
  • 01:14:03your talk. And Thank you.
  • 01:14:04My question is that you
  • 01:14:05started your talk by saying
  • 01:14:06that we have a high
  • 01:14:07rate of mortality.
  • 01:14:08And now you... What you
  • 01:14:10presented, obviously, mace is reduced.
  • 01:14:12The question is that do
  • 01:14:13we reduce the mortality? And,
  • 01:14:15you know, the cabbage which
  • 01:14:16bypasses all this has not
  • 01:14:18shown to be actually reducing
  • 01:14:19mortality. Now, Erica mentioned actually
  • 01:14:21the residual
  • 01:14:23risk, and we talked about,
  • 01:14:24lack of Except for in
  • 01:14:26stitch. Except for in stitch.
  • 01:14:30They, like, opened a little
  • 01:14:31aid. I'd unfortunately wanna trial
  • 01:14:33failed, but I think that
  • 01:14:35that is kind of, what
  • 01:14:37are your thoughts about what
  • 01:14:38to do to actually reduce
  • 01:14:39really mortality?
  • 01:14:41I mean, now, actually, I
  • 01:14:42wanna also mention something that
  • 01:14:43we haven't published yet, but
  • 01:14:44I wanna actually kind of
  • 01:14:45make some people aware here
  • 01:14:47that you reduce the plasma
  • 01:14:49cholesterol,
  • 01:14:50but a lot of,
  • 01:14:51based on genetic study, a
  • 01:14:53lot of diseases that actually
  • 01:14:55increase the cholesterol within the
  • 01:14:56cell because the cholesterol in
  • 01:14:58the plasma is reduced. You
  • 01:14:59take it up, but then
  • 01:15:01it's gonna go to the
  • 01:15:01wrong places such as lysosomes
  • 01:15:03and then causes inflammation but
  • 01:15:04whatnot. And my question to
  • 01:15:07you is that is the
  • 01:15:07intervention gonna do the job
  • 01:15:09for reducing mortality or medical
  • 01:15:11therapy?
  • 01:15:12Yeah. So so I think
  • 01:15:13if we can prevent these
  • 01:15:14things from rupturing in thrombosis...
  • 01:15:17Thrombosing,
  • 01:15:18then we will prevent myocardial
  • 01:15:19infarctions, and that will prevent
  • 01:15:21mortality.
  • 01:15:23So I I totally agree
  • 01:15:24with you. It's it's fine
  • 01:15:25to say we can reduce
  • 01:15:27MACE.
  • 01:15:27And, yes, the unstable angina
  • 01:15:29and unplanned hospitalization,
  • 01:15:32you know, that's a a
  • 01:15:33very unpleasant event. Patients don't
  • 01:15:35want to have that. That's
  • 01:15:36a good thing to prevent.
  • 01:15:37But, yeah, we'd like to
  • 01:15:38have definite, you know, medical
  • 01:15:39evidence that we're reducing CV
  • 01:15:40death and MI to
  • 01:15:42start. And of all the...
  • 01:15:44But this becomes a statistics
  • 01:15:45game. Okay? So, you know,
  • 01:15:47when you're in relatively healthy
  • 01:15:49populations that have good background
  • 01:15:51treatments, their rates are relatively
  • 01:15:53low. So of all those
  • 01:15:54trials I showed you, the
  • 01:15:55one that we're running in
  • 01:15:56China at, thirty one hundred
  • 01:15:58and thirty patients is the
  • 01:15:59only one that's powered for
  • 01:16:01a reduction in cardiovascular death
  • 01:16:02or myocardial infarction.
  • 01:16:04To show a reduction in
  • 01:16:06cardiovascular
  • 01:16:07death or all cause death,
  • 01:16:08you would need over ten
  • 01:16:09thousand
  • 01:16:11patients. And so pharma does
  • 01:16:12that all the time, but
  • 01:16:13they don't do that in
  • 01:16:15targeted vulnerable plaque populations.
  • 01:16:17So I don't see that
  • 01:16:19size trial happening in an
  • 01:16:20interventional trial soon in this
  • 01:16:22field because of the need
  • 01:16:23for imaging. But I think
  • 01:16:25that if we can show
  • 01:16:25a reduction in CV death
  • 01:16:27or MI, that that will
  • 01:16:28be convincing to most people.
  • 01:16:30With that, let me again
  • 01:16:32thank Greg for joining us.
  • 01:16:34Wonderful talk. Thank you. Thanks,.